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Abstract 
 
Human biomonitoring is a widely used method in the assessment of occupational exposure to 
chemical substances and recommended biological limits are published periodically for 
interpretation and decision-making. However, it is increasingly recognized that a large 
variability is associated with biological monitoring, making interpretation less efficient than 
assumed. In order to improve the applicability of biological monitoring, specific factors 
responsible for this variability should be identified and their contribution quantified. Among 
these factors, age and sex are easily identifiable, and present knowledge about pharmaceutical 
chemicals suggests that they play an important role on the toxicokinetics of occupational 
chemical agents, and therefore on the biological monitoring results. 
The aim of the present research project was to assess the influence of age and sex on 
biological indicators corresponding to organic solvents. This has been done experimentally 
and by toxicokinetic computer simulation. Another purpose was to explore the effect of 
selected CYP2E1 polymorphisms on the toxicokinetic profile. 
Age differences were identified by numerical simulations using a general toxicokinetic model 
from a previous study which was applied to 14 chemicals, representing 21 specific biological 
entities, with, among others, toluene, phenol, lead and mercury. These models were runn with 
the modified parameters, indicating in some cases important differences due to age. The 
expected changes are mostly of the order of 10-20 %, but differences up to 50 % were 
observed in some cases. These differences appear to depend on the chemical and on the 
biological entity considered.  
Sex differences were quantified by controlled human exposures, which were carried out in a 
12 m3 exposure chamber for three organic solvents separately: methyl ethyl ketone, 1-
methoxy-2-propanol and 1,1,1-trichloroethane. The human volunteer groups were composed 
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of ten young men and fifteen young women, the latter subdivided into those with and without 
hormonal contraceptive. They were exposed during six hours at rest and at half of the 
threshold limit value. The kinetics of the parent compounds (organic volatiles) and their 
metabolite(s) were followed in blood, urine and expired air over time.  Analyses of the 
solvent and their metabolites were performed by using headspace gas chromatography, 
CYP2E1 genotypes by using PCR-based RFLP methods. Experimental data were used to 
calibrate the toxicokinetic models developed for the three solvents. The results obtained for 
the different biomarkers of exposure mainly showed an effect on the urinary levels of several 
biomarkers among women due to the use of hormonal contraceptive, with an increase of 
about 50 % in the metabolism rate. The results also showed a difference due to the genotype 
CYP2E1*6, when exposed to methyl ethyl ketone, with a tendency to increase CYP2E1 
activity when volunteers were carriers of the mutant allele. Simulations showed that it is 
possible to use simple toxicokinetic tools in order to predict internal exposure when exposed 
to organic solvents. Our study suggests that not only physiological differences but also 
exogenous sex hormones could influence CYP2E1 enzyme activity.  
The variability among the urinary biological indicators levels gives evidence of an 
interindividual susceptibility, an aspect that should have its place in the approaches for setting 
limits of occupational exposure. 
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Résumé 
 
La surveillance biologique est de plus en plus utilisée dans l’évaluation d’expositions 
professionnelles des travailleurs. Il existe des normes biologiques pour plusieurs substances 
chimiques qui ne prennent pas forcément en compte la variabilité interindividuelle. Lorsque 
celle-ci est associée aux systèmes biologiques, les décisions sont souvent difficiles à prendre 
et l’interprétation des résultats n’est pas toujours évidente. Afin d’améliorer l’application de 
la surveillance biologique, il est essentiel d’avoir de très bonnes connaissances de l’impact de 
certains paramètres biologiques, comme l’âge et le sexe.  
Le but général de cette étude était d’évaluer l'influence de l’âge et du sexe sur les indicateurs 
biologiques d'expositions correspondants à des solvants organiques, soit de manière 
expérimentale, soit par la modélisation toxicocinétique. De plus, l'effet de certains génotypes 
du CYP2E1 sur l'activité enzymatique a été étudié à titre exploratrice. 
Les changements toxicocinétiques liés à l’âge ont été évalués par modélisation, à partir d’un 
modèle toxicocinétique simple d’une étude précédente qui a été appliqué à 14 substances 
chimiques, représentant 21 déterminants biologiques, avec, entre autres, le toluène, le phénol, 
le plomb ainsi que le mercure. Ces modèles toxicocinétiques ont été modifiés en prenant en 
compte l’âge.  Après simulation, des  différences de l’ordre de 10 à 20 % ont été observées 
dans la plupart des cas. Néanmoins, pour quelques substances chimiques, des différences 
jusqu’à 50 % ont pu être mises en évidence. Elles semblent dépendre du produit chimique et 
de l’indicateur biologique considéré.  
Des études expérimentales en cabine d’exposition ont permis d’évaluer l’importance des 
changements toxicocinétiques dus au sexe pour trois solvants organiques: la 
méthyléthylcétone, le 1-méthoxy-2-propanol et le 1,1,1-trichloroéthane. Les groupes de 
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volontaires étaient composés de dix jeunes hommes et de quinze jeunes femmes, dont dix 
prenant un contraceptif hormonal. Les participants étaient exposés, au repos pendant six 
heures, à la moitié de la valeur moyenne d’exposition du solvant considéré. Les indicateurs 
biologiques respectifs ont été suivis dans l'urine, le sang ou l'air expiré. Les analyses des 
substances mères et des métabolites ont été effectués par la technique dite headspace en 
chromatographie en phase gazeuse, le génotypage par une technique de PCR/RFLP. Les 
données expérimentales ont servi à valider les modèles toxicocinétiques développés pour les 
trois solvants organiques à partir d'un modèle général existant. Des différences dans les 
niveaux d'indicateurs biologiques ont principalement été observées chez les femmes. Les 
participantes sous prise de contraceptif hormonal ont montré un taux de métabolisme 
augmenté de 50 %. Les résultats ont également indiqués que les volontaires porteurs de 
l'allèle mutant d'un des génotypes étudiés, le CYP2E1*6, auraient une tendance à avoir une 
activité enzymatique plus élevée. Les simulations obtenues à partir des modèles 
toxicocinétiques montrent qu’il est possible d’utiliser un modèle général simple afin de 
prédire l’exposition interne d’une personne lorsque celle-ci est exposée à des solvants 
organiques. Cette étude suggère que les différences toxicocinétiques observées entre hommes 
et femmes ne sont pas essentiellement dues aux différences physiologiques. Les hormones 
sexuelles, et notamment les variétés exogènes, semblent jouer un rôle important dans l'activité 
du CYP2E1.  
La variabilité interindividuelle est par conséquent un aspect qui doit avoir sa place dans 
l'élaboration de valeurs limites professionnelles. 
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1 Introduction 
           
 1.1. Context and motivation 
Since a long time, researchers like Alice Hamilton (1869-1970), the first woman appointed to 
the faculty of Harvard Medical School and a leading expert in the field of occupational health, 
were interested in pointing out the differences in women’s and men’s working and living 
conditions, and how these could differentially affect their health. It is only about the end of 
our century that sex differences in occupational health began seriously to be taken into 
account (Messing and Mergler, 2006). 
Recent publications clearly underlined that we have still little understanding of the impact that 
sex and gender may have on exposure to chemicals, and that more research on women is 
necessary and desirable (Ernstgård et al., 2003; Messing and Stellman, 2006; Arbuckle, 2006; 
Gochfeld, 2007). 
Another concern was underlined by Illmarinen (2001).  He presented the main conclusions 
from European Union statistics on population aging, as for example the fact that workers aged 
of 50 years and more will constitute the largest proportion (> 30 %) of the work force during 
the next 25 years. 
The Swiss Federal Statistical Office published several scenarios of the population evolution 
until year 2050 (SFSO, 2010). After the average scenario, the proportion of children and 
teenagers (0-19 years) will stay more or less stable, with 20.8 % in 2010 and 18.4 % in 2060, 
whereas the proportion of old people (> 64 years) will increase from 17.1 % to 28.3 % during 
the same period. As a matter of fact, the peak of the population pyramid will become 
gradually broader in the next fifty years while its basis stays unchanged. The active 
population will get old in an unquestionable way during this period.  
  22
The understanding of the influence of age and sex is determinant in the context of our new 
economic and work situation. Workers are getting older and older, and as a consequence their 
medication is also increasing (WHO, 2002). Moreover workers are not anymore specifically 
male. 
Biological monitoring is frequently used in exposure assessment and in surveillance of 
workers over time. Biological exposure limits are known for many chemicals and are 
published in several countries (ACGIH, 2010; DFG, 2009) and in Switzerland (SUVA, 2009). 
However variability associated with biological systems often precludes a sound interpretation 
and decision making. To improve applicability of biological monitoring it is essential to have 
more information, and notably to understand the effect of specific modifying factors, such as 
age and sex. With this information, a prior distribution of expected results could be defined 
and serve a better decision making process. This project should contribute to an improvement 
of biological monitoring procedures for the specific chemicals studied, but also for other 
chemicals, using toxicokinetic modelling techniques. 
  
 1.2. Biological monitoring of occupational exposure 
Biological monitoring, which relies on measurements of the chemical or its metabolites in 
biological fluids, is integrated since a long time as a fundamental exposure assessment tool in 
the field of occupational health.  
The first paper on biomonitoring appeared in 1927 and reported the usefulness of the 
determination of urinary lead when diagnosing lead-induced industrial disease (Aitio, 2006).  
Besides metals, the organic solvents represented another important family of substances on 
industrial scale. Their production and use increased mainly in the latter half of the 19th 
century due to the coal-tar industry. They can be mainly classified as aliphatic hydrocarbons, 
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cyclic hydrocarbons, aromatic hydrocarbons, halogenated hydrocarbons, ketones, amines, 
esters, alcohols, aldehydes, ethers and glycol ethers. During the 1980's, a major concern for 
occupational hygienists and physicians was to assess the risk of occupational exposure to 
volatile organic compounds (Droz et al., 1983) as their neurotoxicity represented one of the 
most important emerging issues in the field of occupational health (Baker 1988). 
Due to their chemical properties, organic solvents are still commonly used worldwide in 
different industrial sectors as degreasing and diluting agents.  
A key component in protecting workers from chemical agents is the concept of biological 
exposure indices (BEIs), which are reference values used as guidelines for the evaluation of 
potential health hazards related to a substance (Morgan, 1997). The large industrial use of 
metals and organic solvents over the last decades and in parallel the scientific studies related 
to them contributed to the establishment of the first recommended biological exposure limit 
values. Most BEIs are based on a direct correlation with the threshold limit values (TLVs). 
The latter refer to airborne concentrations of chemical substances and represent conditions 
under which it is believed that nearly all workers may be repeatedly exposed, day after day, 
over a working lifetime, without adverse health effects (ACGIH, 2010). 
Biological monitoring results are in many cases interpreted on an individual basis, despite 
their quite often large variations for the same individual over time and between individuals. 
These variations in biological levels are usually not associated with corresponding exposure 
changes, nor with health effects, as biomarkers are very often not the toxicologically active 
species, at least for solvents. Biomarkers are thus in most cases used as indirect indicators of 
exposure, assuming a fixed relationship between them for a given chemical. Any factor 
affecting this relationship will thus introduce some uncertainty reducing decision making 
possibilities. 
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Recently more and more attention has been devoted to variability associated with biological 
monitoring results (Pierrehumbert et al., 2002; Tardif et al., 2002; Truchon et al., 2006; 
Berthet et al., 2010; Thomson et al., 2010). This aspect of biological monitoring was often not 
considered and results were used without paying much attention to the associated uncertainty. 
Several studies in volunteers and with toxicokinetic models have now shown that biological 
results follow approximate lognormal distributions, characterized by geometric standard 
deviations ranging from about 1.3 to 2.0 (Droz, 1992), equivalent to a coefficient of variation 
between 30 and 100 %. This large biological variability was already obvious to drug 
therapists (Meibohm, 2002; Schwartz, 2003), and adaptation of dosage is quite current 
practice, at least for drugs having narrow therapeutic ranges.  
Among others, age and sex are easily identifiable determinants which could play an important 
contribution to biological variability. There is still little understanding of the influence of 
these determinants on exposure to and measurement of occupational chemicals. Several 
authors recommended recently that more toxicokinetic studies should be undertaken to better 
characterize the influence of sex and age (Arbuckle, 2006; Messing, 2006; Gochfeld, 2007). 
In a recent review, Truchon et al. (2004) indicated that the question of the influence of age on 
industrial chemical toxicokinetics has only received little attention until now. They 
recommended that this aspect should be further studied, notably by toxicokinetic modelling, 
to better understand its contribution to biological variability. Truchon et al. (2004), referring 
to Canadian statistics, mentioned that the proportion of aged workers will represent 39 % of 
the active population in 2016, compared to 29 % in 1996.  
Few studies exist about the possible evaluation of sex differences in the toxicokinetics of 
occupational toxicants in humans. Ernstgård et al. (2003a, 2003b) exposed male and female 
volunteers to m-xylene and 2-propanol under controlled conditions. They found toxicokinetic 
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modifications for both chemicals, which they attributed mainly to anatomical differences 
between sexes.  
Biological variability has been taken into account very early in risk assessment procedures, 
probably because the extrapolation between animal species and from high to low doses forced 
the discussion of uncertainty (Dorne, 2005). In that case factors were used to describe 
uncertainty, leading to the establishment of default safety factors (WHO, 1987). Recently, 
attempts have been made to improve or reduce these factors by using various modelling 
techniques for extrapolation (WHO, 2001).  
Several authors started to describe, using various modelling tools, the contribution of age and 
sex to biological variability (Hattis et al., 2003; Clewell et al., 2002). For example, Clewell et 
al. (2004) developed a toxicokinetic model in order to determine the tissue concentration as a 
function of time of some xenobiotics by including age and sex as important parameters, 
representing an initial attempt to provide a predictive toxicokinetic framework. 
 
 1.3. Toxicokinetic modifications due to age and sex 
Toxicokinetic behaviour of chemicals in the body determines biological levels, and thus 
biological indicator results. It is usually described as four processes: absorption, distribution, 
metabolism and elimination. Biological variability results from changes in any of these four 
processes.  
 
 1.3.1. Absorption 
In occupational settings, absorption can occur by inhalation, by ingestion or by skin contact. 
In the present project, only inhalation will be considered. 
Upon aging, lungs become stiffer, muscle strength and endurance diminish, and the chest wall 
becomes more rigid. Total lung capacity remains constant but vital capacity decreases and 
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residual volume increases. The alveolar surface area decreases by up to 20 percent. Alveoli 
tend to collapse sooner on expiration. There is a decrease in the activity and number of cilia 
and an increase in mucus production. All these changes can contribute to reduce the transfer 
of a substance through the pulmonary membrane. When the inhaled product is gaseous, the 
most probable impact of aging on the pulmonary absorption of the substance is a decrease in 
absorption because of the corresponding modifications occurring in the lungs (Wahba, 1983; 
Tockman, 1990). For contaminants present as aerosols, (Elder et al., 2000), there could be a 
decrease in the absorption of the smallest particles. One explanation is that with age, there is a 
possible accumulation of particles in the lungs.  
For sex differences in absorption by inhalation, only limited data are available (Schwartz, 
2003). Overall there are few demonstrated differences in absorption from lung between men 
and women. Ernstgård et al. (2003a,b) carried out a study with volunteers in order to evaluate 
possible sex differences in the inhalation toxicokinetics of a polar (2-propanol) and a nonpolar 
solvent (m-xylene). A limitation of their study was a low number of participants and a low 
exposure level. Nevertheless, the results indicated slight differences between men and 
women. For m-xylene, it seems that body size and body composition were more important 
determinants than sex. For 2-propanol, body build could not explain the difference between 
women and men regarding 2-propanol in expired air and acetone, one of its metabolites, in 
saliva. 
 
 1.3.2. Distribution  
The principal modifications in distribution are due to changes in body composition in the 
elder human. There is a progressive reduction in total body water (about 15 %) and in lean 
body mass, resulting in a relative increase in body fat (about 30 %) (Truchon et al., 2004). 
These changes have an influence on the volume of distribution of the substance. Hence 
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hydrophilic substances tend to have smaller volumes of distribution resulting in higher plasma 
concentration, while for lipophilic substances the volume of distribution increases with age 
and the plasma concentration decreases (Turnheim, 2003).  
The distribution of a chemical agent can also be altered by modifications in protein binding. A 
decrease of about 15 to 20 % is often observed with age in the plasma concentration of 
albumin which binds to many industrial solvent or metabolites (Lichtman, 1995). One can 
therefore expect an increase in free or unbound chemical concentration.  
Female physiological differences such as lower average body weight, higher body fat 
composition, smaller plasma volume and lower average organ blood flow can modify the rate 
and extent of distribution of the chemical in women (Gandhi et al., 2004). Lipophilic 
substances will tend to have a greater distribution volume in women, hydrophilic ones will 
show the opposite (Schwartz, 2003). 
The binding to proteins in the plasma is also influenced by sex hormones, which can lead to 
toxicokinetic differences between sexes (Gandhi et al., 2004). Albumin is a major plasma 
protein responsible for reversible drug binding, but not really affected by sex (Verbeeck et al., 
1984). Schwartz (2003) wrote about an early interest in reports of sex-related differences in 
1-acid glycoprotein concentrations. The protein binding seems to be greater in men than in 
women.  
 
 1.3.3. Metabolism 
The major metabolic organ in the body is the liver. The age-related changes of the liver are a 
decrease of the hepatic mass and of hepatic blood flow (Sellers, 1989; Vestal, 1997). The 
hepatic mass can be decreased by about 20 to 50 %, leading to a reduction of the metabolic 
capacity (George et al., 1995; Vestal, 1997). Since age 25, the total hepatic blood flow 
diminishes from 0.5 % to 1.5 % every year. For a person of 65 years old, this causes a 
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reduction in hepatic blood flow of 35-40 % (Vestal, 1997; LeCouteur and McLean, 1998). 
Hence this could reduce metabolic elimination of a chemical that shows a flow-limited 
behavior.  
Cytochrome P450 dependent mono-oxygenases are the most prominent enzymes involved in 
solvent metabolism. Isoenzymes belonging to the first four gene families (CYP 1-4) are 
involved in the metabolism of xenobiotics (Löf et al., 1998). The metabolism of many 
solvents includes oxidation by the CYP2E1 (Nakajima et al., 1997). This specific isoform, 
probably among others, is known to have an activity increasing with age, to exhibit sex 
differences and to show a polymorphism (Bebia et al., 2004). It is well known that the overall 
P450 activity is also changing with age, more specifically for some P450 isoforms, such as 
the CYP3A family.  
Studies showed that the decrease in metabolism with increasing age seems to be mainly 
related to changes in the activity of liver enzymes (Geller and Zenick, 2005), while others 
mentioned that it could come from the decline in liver volume and blood flow (Schmucker, 
2001). In both cases the result can be a slowed detoxification of chemical compounds. 
Anantharaju et al. (2002) mentioned that the majority of the drug interactions in the elderly is 
related to the hepatic metabolism by multiple enzyme systems including cytochrome P450, 
which is supported by a study done by Sotaniemi et al. (1997). The conclusion is the 
following: “This study shows a reduction of in vitro and in vivo drug metabolism with age in 
humans. The data suggest that at least three age groups—young, middle-aged, and elderly—
should be included in the evaluation of the pharmacokinetics of a new drug. Cytochrome 
P450 content in subjects from 20 to 29 years of age was 7.2 ± 2.6 nmol · gm−1, increased 
during the fourth decade (+ 7.2%, p = NS), declined after 40 years (−16%, p < 0.01) to a level 
that remained unaltered up to 69 years, and declined further after 70 years (−32%, p < 
0.001).” 
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LeCouteur and McLean (1998) proposed an alternate mechanism based on oxygen delivery 
(phase I enzymes are directly dependent on oxygen supply as a substrate) in order to try to 
resolve this paradox of phase I drug metabolism presented by Schmucker (2001). McLean and 
Le Couteur (2004) concluded that “hepatic clearance of flow-limited drugs is reduced 
secondary to age-related reduction in hepatic blood flow, and drug clearance may also be 
influenced by age-related changes in hepatic sinusoidal endothelium.” 
A large body of literature comparing clearance of hepatically metabolized substances in men 
and women exists regarding the differences in metabolism due to sex (Schwartz, 2003). The 
large interindividual variability in amount and activity of the individual enzymes makes it 
difficult to demonstrate sex-dependent differences in metabolism (Anderson, 2005). 
According to Schwartz (2003), most metabolic routes show a higher or similar clearance in 
men compared to women. But differences have been identified in activities for CYP1A2, 
CYP3A4, CYP2D6, and CYP2E1. Those enzymatic activities are usually higher in males than 
in females (Tanaka, 1999; Clewell et al., 2002; Parkinson et al., 2004). 
 
 1.3.4. Excretion 
The most important pharmacokinetic change in the elderly is the reduction in renal 
elimination (Turnheim, 2003). The age-related changes for the kidneys are a decrease in the 
renal mass and renal blood flow. Between 40 and 90 years, the decrease of the renal mass is 
about 30 % (Yuen, 1990; Evers et al., 1994; Gleason, 1996). Glomerular filtration decreases 
about 1 ml/min per year after 40 years (Evers et al., 1994). The renal blood flow diminishes 
about 1 % per year after the age of 50 (Yuen, 1990; Gleason, 1996; Vestal, 1997). There are 
also other renal functions like the renal clearance that decrease with the elderly (Evers et al., 
1994). The urinary excretion of creatinine is also affected by age. At 65 years, there is a 
decrease of about 15 to 25 % comparatively to someone of 20 years old. This change is 
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explained by a decrease of renal mass and glomerular filtration (Alessio et al., 1985; Boeniger 
et al., 1993). These modifications lead to a reduction of the elimination of chemicals and their 
corresponding metabolites (Evers et al., 1994; Vestal, 1997).  
Sex-related differences in glomerular filtration, tubular secretion and tubular reabsorption 
have been pointed out (Schwartz, 2003). Glomerular filtration rate is 10 % lower in females 
than in males after correction for body size (Gross et al., 1992). The effect of sex on renal 
secretion and renal reabsorption is less clear (Schwartz, 2003). Creatinine clearance rates are 
generally higher in males than in females and lower during the first week of menses than later 
in the cycle (Arbuckle, 2006). 
 
 1.4. Organic solvents 
Due to their chemical properties, organic solvents are a family of chemical substances that are 
commonly used worldwide in different industrial sectors as degreasing and diluting agents or 
in consumer products as detergents or emulsifiers. The experimental part of the present study 
focused on chemical exposures to organic solvents and in order to be able to quantify 
toxicokinetic differences due to sex, three solvents have been selected based on their wide 
practical use, their relatively low toxicity, and their metabolic and physiological properties.  
Methyl ethyl ketone (MEK), with a TLV of 200 ppm (Suva, 2009), is water soluble and 
highly metabolized. MEK is metabolized to 2,3-butanediol, 2-butanol and 3-hydroxy-2-
butanone (major metabolite), all excreted in urine. A low fraction of unchanged solvent is 
excreted in the exhaled air and in urine. The urinary concentration of MEK at the end of the 
shift has been recommended as the most appropriate biological exposure indicator.  
MEK is used as a solvent in the application of protective coatings (varnishes) and adhesives 
(glues and cements). It is also commonly used in paint removers, cleaning fluids, acrylic 
  31
coatings, pharmaceutical production, and colorless synthetic resins, and as a printing catalyst 
and carrier. Occupational exposure can occur mainly by inhalation and by dermal uptake.  
The main effects during acute exposure have been described to be irritation symptoms (eye, 
nose, throat) (INRS, 2009). These are general moderate and can begin at half of the TLV. 
Recent studies showed that exposure to 200 ppm during 4 hours had no significant effect in a 
variety of behavioural and psychological tests.  Symptoms as headaches or gastrointestinal 
upset, or even central nervous system disorders, can appear at higher exposure concentrations. 
Case reports of encephalopathies and peripheral neuropathies have been described during 
chronic exposures to MEK but in general, exposure occurred to a mixture of solvents. Chronic 
dermal contact can result in dermatoses. Industrial exposure to moderate levels of MEK is 
widespread but these levels can be much higher due to inadequate ventilation systems. 
1-Methoxy-2-propanol (1M2P), with a TLV of 100 ppm (Suva, 2009), is also water soluble 
and highly metabolized. 1M2P belongs to the family of the propylene glycol ethers (PGE) 
which exists under the form of two isomers, alpha-isomer and beta-isomer. The latter one, 
considered as an impurity in commercial use, is first transformed as all primary alcohols into 
2-alkoxy acetaldehydes by alcohol deshydrogenases, and then into alkoxyacetic acids by 
aldehyde deshydrogenases, a toxic metabolite. Alpha-PGE are primarily metabolized to 
propylene glycol, carbon dioxide and glucuronide as well as sulfate conjugates of the parent 
compound. The urinary 1M2P concentration at the end of the shift corresponds as the 
appropriate biomarker. 
1M2P is used in a wide variety of industrial and commercial products, primarily water-based 
paints, varnishes and inks. 
In the case of acute exposure above 100 ppm, main effects are similar to those observed when 
exposed to MEK, that means irritation symptoms in the area of the nose, the eyes and the 
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throat (INRS, 2010). Neurological effects are observed for concentrations of 1M2P above 
1000 ppm. There is no data in literature about toxic effects in humans due to chronic exposure 
to 1M2P. 
Occupational exposure can occur mainly by inhalation and dermal absorption. A field study 
(Devanthéry et al., 2000) showed that workers in an ink factory can be exposed to a third or 
half of the TLV, indicating that air levels of 1M2P in industry can be important. 
1,1,1-Trichloroethane (111TCE), with a TLV of 200 ppm (Suva, 2009), is liposoluble and 
slowly metabolized. 111TCE is metabolised to trichloroethanol (TCE) and trichloroacetic 
acid (TCA), both excreted in urine. Other minor metabolites (carbon dioxide, acetylene) are 
excreted in the exhaled air. The corresponding biological exposure indices are the urinary 
concentration of both metabolites and the blood concentration of the parent compound. The 
111TCE concentration in the exhaled air can also be considered as a biomarker of exposure. 
111TCE has been largely used particularly as degreasing agent or as a solvent for inks, paints, 
adhesives and other coatings. The Montreal Protocol targeted 111TCE as one of those 
compounds responsible for ozone depletion and banned its use beginning in 1996. Thus, its 
manufacture and use has been phased out throughout most of the world.  
111TCE was once used for anesthesia, en effect that could be reached by inhalation of 10 000 
to 26 000 ppm (INRS, 2007). Inhaled 111TCE can thus act as a central nervous system 
depressant and can cause effects similar to those of intoxication, including dizziness, 
confusion, and in sufficiently high concentrations, cardiac disorder (ventricular fibrillation), 
unconsciousness and death. Chronic exposure to 11TCE vapors can lead to skin, eyes and 
respiratory irritations. 
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The three solvents are mainly absorbed by inhalation and metabolized via the cytochrome 
P450 mixed-function oxidase system, with the cytochrome CYP2E1 as the main enzyme 
involved in the metabolism of organic solvents. They are well known and studied, both in 
volunteers and in workers, but there is no data available on the effect of age and sex on their 
toxicokinetics in humans.  
 
 1.5. Gaps in knowledge 
It is presently very difficult to understand quantitatively the variability associated with 
biological monitoring results. Although we can establish a list of contributing factors, as 
shown in a framework for age differences by Geller and Zenick (2005) and a framework for 
sex differences by Gochfeld (2007), their relative importance is unknown for different 
chemicals of occupational interest. It is therefore presently impossible to use such information 
to reduce uncertainty due to biological variability and make safer quantitative decisions when 
using biological monitoring of exposure. 
There is only very limited information about changes in biological indicators of exposure with 
age and sex. When available it is restricted to a few chemicals and to some specific situations 
only. However, changes in physiological parameters, and even metabolic functions, with age 
and sex are rather well known. The same is valid when looking at pharmaceutical drugs for 
which we have a deeper experience. The general goal of the present project is therefore to 
integrate this available information (namely physiological, metabolic and pharmaceutical) in a 
quantitative framework in order to be able to understand the effect of age and sex on 
biological monitoring of occupational exposure. 
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2 Objectives 
 
The main objective of the present research project was to assess the influence of age and sex 
on biological levels of some important chemicals and their metabolites in the human body. 
Compartmental toxicokinetic models developed in previous studies for a series of metallic 
and organic compounds were used to describe the differences due to age. The approaches 
applied to study the influence of sex on the chemical disposition of three specific organic 
solvents (MEK, 1M2P, 111TCE) were human volunteer exposures under controlled 
conditions in an experimental exposure chamber and toxicokinetic modelling using 
compartmental models. Furthermore another purpose was to explore the influence of 
toxicogenetic polymorphism (CYP2E1) on urinary levels of the studied biomarkers.  
Results will indicate if the variability due to age and sex is important and if it depends on the 
chemical. The information obtained, the models developed and the understanding reached 
will be of great use in interpreting biological monitoring data in occupational exposure 
assessment. The use of toxicokinetic models will allow a mechanistic description and the 
extrapolation of data gathered on a few chemicals to other substances of industrial interest. 
The aim was not to adapt exposure limits for the aged active population and for the male-
female differences but it was to better understand the contribution of age and sex to biological 
variability, in order to take it into account when assessing exposure of individuals. 
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3 Results 
 
Paper I: Several work in toxicokinetic modelling has been done during the first year of the 
PhD. Specific factors responsible for interindividual variability should be identified and their 
contribution quantified in order to improve the usefulness of biological monitoring. Among 
others, age is an easily identifiable determinant which could have an important impact on 
biological variability. A compartmental toxicokinetic (TK) model developed in previous 
studies for a series of metallic and organic compounds was applied to the description of age 
differences. Young male physiological and metabolic parameters, based on reference man 
information, were taken from preceding studies and were modified in order to take into 
account age based on available information about age differences. Numerical simulations 
using the kinetic model with the modified parameters indicate in some cases important 
differences due to age. The expected changes are mostly of the order of 10-20 %, but 
differences up to 50 % were observed in some cases. These differences appear to depend on 
the chemical and on the biological entity considered. This work has been published in the 
form of a short communication in International Archives of Occupational and Environmental 
Health 2009, 82(5): 669-676. 
 
Paper II: The analytical work of the project represented an important part, leading to the 
improvement of one of the existing methods at the institute for the determination of urinary 
1M2P. The existing method for the determination of urinary 1M2P included a solid-phase 
extraction and derivatization before analysis by gas chromatography coupled to a flame 
ionization detector (Devanthéry et al., 2000). First essays had been done formerly in the frame 
of a planned study on mouse 1M2P exposure (unpublished results), by modifying the existing 
method and then by replacing it because it could not achieve enough sensitivity with 
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microvolumes of biological fluids. Thus, there was an obvious need to develop a sensitive, 
reliable, alternative method.  
Moreover, glycol ethers still continue to be a workplace hazard due to their important use on 
industrial scale. Currently, chronic occupational exposures to low levels of xenobiotics are 
increasingly relevant. Thus, sensitive analytical methods for biomarkers of exposure are of 
interest in the field of occupational exposure assessment.  
For 1M2P, with a vapor pressure of 12 mmHg (1.60kPa), the headspace technique was a 
suitable option to extract this alcohol from biological fluid as applied to different organic 
volatiles. The determination of urinary 1M2P by the headspace technique was proposed, as it 
consisted in a highly sensitive and a particularly simple analytical method, useful in the 
assessment of occupational exposure to 1M2P. Furthermore, the analytical procedure could 
easily be adapted for other substances of the glycol ethers family if their physico-chemical 
properties allow it.  
In comparison to the former existing analytical method, several aspects have been improved. 
The influence of the salt addition on the partition coefficients in gas-water systems with the 
enrichment of compounds of interest in the “head space” phase is a crucial factor to improve 
the sensitivity of analysis. The limit of detection obtained under the described conditions was 
much lower (10 fold better). With a limit of detection of 0.1 mg/l, the GC headspace 
technique allows to determine the target substance in small volumes of biological fluids 
and/or in low occupational exposures situations. This work has been published under the form 
of a technical note in Analytical and Bioanalytical Chemistry 2010, 396(7): 2709-2714. 
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Paper III: The main part of this project concerned the experimental study with human 
volunteers. The aim was to quantify the variability on biological indicators between men and 
women for three well known solvents: MEK, 1M2P and 111TCE. These three volatile 
chemicals have been studied both in volunteers and in workers but there is no data available 
on the effect of sex on their toxicokinetics in humans. Another purpose was to explore the 
effect of selected CYP2E1 polymorphisms on the toxicokinetic profile. 
At the beginning of the project, four different groups of volunteers had been established 
(young women and young men of 20-25 years, aged women and aged men of 55-65 years) 
and four chemicals had been chosen for the experimental part of the present study. First 
human exposures began in December 2007, with six young male volunteers. After these 
exposure sessions, the next step was to include aged volunteers where major problems have 
been encountered. During several months, the volunteer research was concentrated on this age 
category (CHUV, “Université populaire” and “Université du 3ème âge” in Lausanne, 
announcement in journals and in commercial centers, word-of-mouth advertising). As the 
experimental protocol was rather restrictive, it was difficult to find any potential aged 
volunteer as it is a reality that this class of the society often does not have enough time to 
participate in such a study or is under medication which was contrary to the severe inclusion 
criteria. The thesis committee proposed at the intermediate evaluation in October 2008 to 
concentrate the volunteer research especially on young men and women and if necessary to 
reduce the number of solvents from four to three. Human exposures continued from January 
2009 until June 2009. About 40 exposure sessions had been performed in total, with fifteen 
young women and ten young men.  
Controlled human exposures were carried out in a 12 m3 exposure chamber for each solvent 
separately, during six hours at rest and at half of the threshold limit value.  
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Results mainly showed an effect on the urinary levels of several biomarkers among women 
due to the use of hormonal contraceptive, with an increase of about 50 % in the metabolism 
rate. Moreover a statistically significant difference due to the genotype CYP2E1*6 with a 
tendency to increase CYP2E1 activity was observed when volunteers were carriers of the 
mutant allele. 
Our study suggests that exogenous sex hormones could influence CYP2E1 enzyme activity. 
For same exposure conditions, biological exposure indices can differ between men and 
women, which can lead to a misinterpretation of biomonitoring results. This aspect should 
have its place in the approaches for setting limits of occupational exposure. These results have 
been accepted for publication in Toxicology Letters (doi:10.1016/j.toxlet.2011.01.032). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Exposure chamber at the Institute for Work and Health in Lausanne, Switzerland  
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Paper IV: Pierrehumbert et al. (2002) have developed a general compartmental model in 
order to quantify the effect of human variability on a wide range of biological exposure 
indices (BEIs). By applying it to four chemicals (toluene, phenol, lead and mercury), they 
showed its potential to be used for further substances. We actually underlined this potential of 
the model by adapting it to three other compounds which are MEK, 1M2P and 111TCE, the 
three organic solvents chosen for the human volunteer study (see Paper III).  
The first step was to calibrate the toxicokinetic models with the experimental data, thus 
simulation conditions corresponded to the exposure conditions, that means six hours at rest to 
the half of the threshold limit value. In a second step, simulations were done within working 
conditions, which means exposure was considered to last 8 h per day, 5 days per week. 
Physical activity was set at 50 W for 12 h per day, and at rest for the resting 12 hours. The 
exposure concentration corresponded to the threshold limit value. The simulated urinary 
levels of the biomarkers were compared to their corresponding biological exposure indices.  
Our results showed that it was possible to use an existing generic toxicokinetic model for 
other compounds by adapting it to every studied organic solvent. In fact, most of the 
simulation results showed good agreement with the experimental data obtained.  
Thus, a general and simple toxicokinetic model, adapted for three well known organic 
solvents, allowed us to show that metabolic parameters can have an important impact on the 
urinary levels of the corresponding biomarkers. Indeed, experimental data pointed out that for 
same exposure conditions, men and women can show a difference of 50 % among the urinary 
biological indicators levels. Moreover, when running the models by simulating industrial 
working conditions, these differences could even be more pronounced. Anyway these 
observations give evidence of an interindividual susceptibility, an aspect that should have its 
place in the approaches for setting limits of occupational exposure.   
 
  42
  43
 3.1. Paper I 
  
Age differences in biological monitoring of chemical exposure. A tentative description 
using a toxicokinetic model. 
 
Tomicic Catherine1, Droz Pierre-Olivier1 
1Institute for Work and Health, Lausanne University, Lausanne, Switzerland 
 
Abstract 
Specific factors responsible for interindividual variability should be identified and their 
contribution quantified in order to improve the usefulness of biological monitoring. Among 
others, age is an easily identifiable determinant which could play an important impact on 
biological variability. A compartmental toxicokinetic (TK) model developed in previous 
studies for a series of metallic and organic compounds was applied to the description of age 
differences. Young male physiological and metabolic parameters, based on reference man 
information, were taken from preceding studies and were modified in order to take into 
account age based on available information about age differences. Numerical simulations 
using the kinetic model with the modified parameters indicate in some cases important 
differences due to age. The expected changes are mostly of the order of 10-20 %, but 
differences up to 50 % were observed in some cases. These differences appear to depend on 
the chemical and on the biological entity considered. Further work should be done to improve 
our estimates of these parameters, by considering for example uncertainty and variability in 
these parameters.  
 
Keywords age · toxicokinetic · modeling · biological indicators 
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Introduction 
Biological monitoring is a method widely used by occupational physicians to estimate 
chemical exposure. However it is more and more often recognized that a large variability is 
associated with biological monitoring, making interpretation less efficient than foreseen 
(Truchon et al. 2006). 
Toxicokinetic behaviour of chemicals in the body determines biological levels, and thus 
biological indicator results. It is usually described as four processes: absorption, distribution, 
metabolism and elimination. Biological variability comes from changes in these four 
processes.  
In a recent review, Truchon et al. (2004) indicate that the question of the influence of age on 
industrial chemical toxicokinetics has received little attention. They recommend that this 
aspect should be further studied, notably by toxicokinetic modeling, to better understand its 
contribution to biological variability. A few authors have started to describe, using various 
modeling tools, the contribution of age to biological variability. Some authors have described 
differences between children and adults (Kreuzer at al. 1997, O’Flaherty 1998, Hattis et al. 
2003) and others have also taken in account the elderly (Jeandel et al. 1992, Clewell et al. 
2002, Clewell et al. 2004). Hattis et al. (2003) drew on individual data for pharmacokinetic 
and anthropometric parameters to help define distributions that will be helpful for population 
distribution modeling of pharmacokinetic differences between children of various ages and 
adults. Clewell et al. (2004) presented an initial attempt to provide a predictive 
pharmacokinetic framework in order to evaluate the potential impact of age- and gender-
specific differences on risk from chemical exposure. The validation of these chemical-specific 
model predictions has been made with only young adult data. 
It is presently still difficult to understand quantitatively the variability due to age associated 
with biological monitoring results. Although it is possible to establish a list of contributing 
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factors, as shown in a framework for age differences by Geller and Zenick (2005), their 
relative importance is unknown for different chemicals of occupational interest. It is therefore 
presently unfeasible to use such information to interpret biological variability and make safer 
quantitative decisions when using biological monitoring of exposure. 
In preceeding studies, Truchon et al. (2003) have developed toxicokinetic tools to describe the 
influence of specific factors on biological levels, such as body build, physical workload, 
metabolic and excretion functions (Pierrehumbert et al. 2002; Truchon et al. 2006) but not 
age. One of these tools, namely a simple toxicokinetic model, was applied in the present study 
to better understand the influence of age on biological exposure indicators. The report in 
question represents a tentative quantitative estimation of the effect of age on biological levels 
of several industrial chemicals and their metabolites. It is then applied to specific biological 
monitoring reference values. 
 
Methods 
Compartmental toxicokinetic model 
A compartmental TK model developed in previous studies (Pierrehumbert et al. 2002) was 
applied to the description of age differences. The TK model (see Figure 1 taken from 
Pierrehumbert et al. 2002) includes physiological parameters defining volumes and flows in 
order to be able to mimic age changes. It was adapted for each chemical according to 
available data and toxicokinetic information.  
The route of absorption by inhalation is represented in the model. In fact most of BEIs are 
based on a direct correlation with the TLVs which indicate the potential « inhalation » 
exposure of a worker. Skin exposure is not included in the models. The chemical is 
distributed between the central compartment and the peripheral one, or storage compartment. 
These compartments can be illustrated by different tissus, depending on the chemical. The 
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distribution can be either flow or diffusion limited and includes the permeability and affinity 
of the tissue for the chemical. The metabolism can give one or more metabolites, and can 
occur by serial or parallel metabolism. Elimination is represented by excretion in expired air, 
feces and urine, or by metabolism. Information on the peripheral compartment when it exits 
can be found in Table 2. The central compartment is then composed of the resting tissues. The 
model is completely described by Pierrehumbert et al. (2002). The TK model was 
implemented in the simulation software ITHINK ANALYST (version 7.02 for Windows, 
High Performance System Inc., Hanover, NH, USA). 
 
Figure 1 Schematic diagram of the TK toxicokinetic model 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physiological and metabolic parameters 
Young male physiological and metabolic parameters were taken from preceding studies and 
are based on reference man information (Tardif et al. 2002). These parameters, used to 
estimate specific data required for each chemical, were modified to take into account age 
based on known information about age differences. A 65-year old man has been choosen, 
based on the legal retirement age in Switzerland, in order to model differences due to age. 
Furthermore the present simulations do not take into account the apparition of various 
diseases with age and the increase use of medications. The main parameters required by the 
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model structure are body weight, cardiac output, blood flows and volumes of the relevant 
tissues, renal clearances and metabolic constants. The detailed list of the parameters 
considered is presented in Table 1.  
 
Changes in physiological and metabolic parameters 
Clewell et al. (2004) developed separate sets of growth- and age-related equations. These 
relations give an increase in bodyweight of 5.5 % from 25 to 65 years.  
There is controversy about the effect of age on cardiac output. It has been described to decline 
with age (Birnbaum 1991). Clewell et al. (2004) have developed an age-related equation for 
cardiac output with data obtained from Åstrand (1983) and show a difference of about 10 % 
between 25 and 65. According to Tonner et al. (2003), cardiac output decreases in an almost 
linear fashion after the third decade of life, with a rate of about 1 % per year in healthy 
individuals without prevalent cardiac disease. This would be a difference of 30 % between 25 
and 60. Fagiolino et al. (2006) indicate that cardiac output diminishes throughout life, 
changing 1 % every year after the age of 25. On the other hand, Rodeheffer et al. (1984) 
demonstrate that there is no significant decline in cardiac output at rest or during exercise in 
healthy adults between the ages of 25 and 79 years. However, aging does alter the mechanism 
by which cardiac output is maintained during exercise. Ribera-Casado (1999) insists on the 
fact that in healthy elderly people, cardiac output remains practically unchanged. Ferrari et al. 
(2003), in a review about age and cardiovascular system, show that cardiac output is 
preserved with age in the resting heart.  Based on these last references, cardiac output was 
considered here to remain unchanged with age for modeling purposes. 
Concerning body composition, there is a progressive reduction in total body water and lean 
body mass, resulting in a relative increase in body fat with age (Mangoni and Jackson 2003). 
According to the ICRP (1975) the body fat fraction of weight is about 11 % for a 20-year-old 
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man and about 30 % for a 70-year-old man. Several authors (Kyle et al. 2001, Turnheim 
2003, McLean and Le Couteur 2004) mention that body fat increases by 20 to 40 % and body 
water decreases by 10 to 15 % in old age. For the TK models, body fat was considered to 
increase by 30 % with age. 
Clewell et al. (2004) analyzed data on brain and liver weights as fractions of body weight for 
a Japanese population. A calculation shows that the variation of liver volume between 25 and 
65 is about 6 %. Le Couteur and McLean (1998) show that in general the reduction of liver 
size with age is noted to be of the order of 25 to 35 %. After the report of the task group on 
reference man, liver weight decreases particularly after an age of 70 (Snyder et al., 1975). 
Chouker et al. (2004) have developed formulas for the estimation of liver size upon data 
obtained on liver weight from 728 legal autopsies analyzed with respect to gender, age, body 
height, body weight, body mass index, and body surface area. From these data, the decrease in 
liver size is about 8 % between age 25 and age 65. Finally, on base of the formulas developed 
by Chouker et al., a decrease of 8 % has been retained for the TK models simulations. 
Several authors describe the decrease of the kidney weight with age (Löf and Johanson 1998, 
Mühlberg and Platt 1999, McLean and Le Couteur 2004, Geller and Zenick 2005). The aging 
kidney shows a decrease in weight of about 20 to 30 %, especially in the 70s and 80s (Silva 
2005). Epstein (1996) mentions a decline in male kidney weight of 19%.  For the TK models, 
a variation of 20 % has been fixed. 
Renal blood flow decreases after the forth decade by about 10 % each decade (Silva 2005) 
and this is not related to cardiac output. A variation of 25 % was thus included in the TK 
models.  
Age-related declines in hepatic blood flow ranging between <0.5 to 1.5 % per year have been 
reported (Schmucker 2001). This would produce a greater than 40 % decline between 25 and 
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90 years of age. According to Anantharaju et al. (2002), when comparing subjects less than 40 
years to those over 65 years, there is a decrease of 35 % in hepatic blood flow. Zoli et al. 
(1999) found a decrease of about 20 % between subjects under 45 years and subjects between 
61 and 75 years. Based on this information, a 20% reduction in hepatic blood flow was 
chosen for the TK models. 
Clewell et al. (2004) calculate the age-specific metabolism rates by using the adult 
metabolism rate, the adult liver volume, the age-specific liver volume and the appropriate 
linearly interpolated fractional activity (gives enzyme activity as a fraction of the adult level). 
Different enzyme systems have been taken in account: CYP2E1, CYP1A2, CYP2C, ADH. As 
these fractional activities do not change between the young adult and the old adult, the 
changes of the metabolism rates will depend on the liver volume. For our TK models, we 
decided to use the same variation as for the liver volume, which is about 8 %. 
The parameter which often determines renal function is the glomerular filtration rate. Clewell 
et al. (2004) describe the age-related differences for urinary clearance parameters by a set of 
equations based on data on glomerular filtration rates. The variation is about 25 % between a 
person of 25 years and one of 65 years. According to Epstein (1996) and Mühlberg and Platt 
(1999), those variations for the same ages can be about 30 %, after a widely used formula 
developed by Cockcroft and Gault (1976) for estimating the creatinine clearance. Berg (2006) 
shows similar differences by using other methods (clearances of inulin and para-
aminohippurate) for evaluating the glomerular filtration rate.  
The skeleton bone tissues also show some decrease with age. The loss of bone has been 
estimated to be about 5-10 % per decade, beginning at about 30 years of age (Snyder et al., 
1975). A value has been fixed at 20 % for the simulation of a young and an old individual.  
No value has been estimated for the richly perfused tissues fraction of bodyweight because of 
a lack of information.  
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Table 1 summarizes physiological and metabolic data used in the model in term of changes 
between 25 and 65 years.  All the values of the parameters that are chemical dependent can be 
found in detail in Truchon et al. (2003). 
 
Table 1 Parameters used in the TK models. Age-related changes in physiological and 
metabolic parameters (age 65 compared to age 25) 
 
 
Parameter 
Unit(3) 
Value(1) 
Age 25 
Rest  50W Variation Reference for the variation 
BW Body weight kg 70 +5.50% Clewell et al. 2004 
Qc Cardiac output l/h/kg0.7 18.0  30.8 = Ribera-Casado 1999 ;  Ferrari et al. 2003  
FVTBW Total body water (TBW) l/kg 0.62 -15% McLean and Le Couteur 2004 
FVfat Fat fraction of body weight l/kg 0.19 +30% Kyle et al. 2001 
FVliver Liver fraction of body weight l/kg 0.026 -8% Chouker et al. 2004 
FVkidney Kidney fraction of body weight l/kg 0.004 -20% Epstein 1996; Silva 2005  
BFfat Fat fraction of cardiac output - 0.05  0.06 + 30% Clewell et al. 2004 
BFliver Liver fraction of cardiac output - 0.26  0.16 -20% Zoli et al. 1999 
BFkidney Kidney fraction of cardiac output - 0.11  0.20  -25% Silva 2005 
kur Urinary excretion rate l/h/kg0.82 1.848 -30% Epstein 1996 ; Clewell et al. 2004 
kcr Creatinine excretion rate mol/h/kg0.9 12.06 -30% Epstein 1996 ; Clewell et al. 2004 
RC Renal clearance l/h/kg-0.3 -
(2)
-30% Epstein 1996 ; Clewell et al. 2004 
KM Michaelis-Menten constant mol/l -(2) -8% Clewell et al. 2004 
VM Michaelis-Menten maximal rate  mol/h/kg0.75 -(2) -8% Clewell et al. 2004 
(1) Truchon et al. 2003 
(2) Values are chemical dependent 
(3) The reference values are adjusted to the body surface using a formula where body weight is related to 
the body surface when raised at a given power. 
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Exposure scenarios 
Repeated occupational exposures were simulated at the current Threshold Limit Values (TLV) 
(ACGIH 2007): 8 hours per day, 5 days per week until steady-state was reached in the tissues. 
For the compounds having long half-lives, steady state was also reached, by adding for 
example an initial dose in the central compartment or by simulating the model over long 
exposure times. Physical workload was set at 50W during 12 hours (including the 8 hours of 
exposure), and at 0W the remaining of the day. 
 
Results 
Modeling age differences in biological levels 
The TK model was applied to 14 chemicals, representing 21 specific biological entities. These 
chemicals are examples among the list of BEIs (Truchon et al. 2003). For each chemical, 
important physiological and metabolic parameters were identified and included in the model 
structure (Pierrehumbert et al. 2002). Results obtained while simulating the influence of age 
are summarized in Table 2 for ages 25 and 65 years.  
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Table 2 Tentative predictions of age-related changes in biological levels of some occupational 
chemicals and their metabolites (age 65 compared to age 25) 
Biological indicator Relative change [%] Peripheral Relative change [%] Relative change [%] Relative change [%] 
  in Ccentral comp.,blood compartment in Cperipheral comp. in Cmetabolite comp.,blood in Cexcretion,urine
  Age 65 vs Age 25   Age 65 vs Age 25 Age 65 vs Age 25 Age 65 vs Age 25 
Arsenic 1.0       -14.5 
 - methylarsonic acid       11.3 -24.0 
 - methylarsinic acid       63.7 53.0 
Cadmium 32.4 kidneys 17.9   10.5 
Chromium (VI) 21.9 rpt* 20.4   14.1 
Cobalt 7.8 rpt* 6.2   -11.6 
2-Ethoxyethanol 6.2         
 - 2-ethoxyacetic acid       38.3 34.8 
Ethylbenzene 0.3 fat 1.8     
 - mandelic acid         10.3 
Fluorides 31.5 skeleton 35.9   22.9 
Lead 25.8 skeleton 18.9     
Manganese 27.2 liver 48.2   7.0 
Mercury 27.9 kidneys 47.5   16.7 
Methyl isobutyl ketone 19.8 fat 17.7   44.0 
Pentachlorophenol 33.5       7.3 
 - conjugated pentachlorophenol         10.7 
Phenol 28.7       20.4 
Toluene 3.2 fat 5.1     
 - hippuric acid       29.8 13.6 
 - o-cresol         10.9 
 
*rpt = richly perfused tissues 
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These preliminary simulations indicate in some cases considerable differences due to age. 
Moreover these differences appear to depend on the chemical and the biological entity 
considered. For some of them age does not seem to affect biological level, for others 
toxicokinetic calculations tend to show that age is an important determinant.  
Changes are of the order of 10 to 30 % for almost half the chemicals simulated by the TK model. 
About a quarter of the substances shows differences less than 10 % and for the resting quarter 
variations are over 30 %, with two examples up to more than 50 %. 
 
Application to biological monitoring data 
Predictions presented in Table 2 can be applied to biological monitoring of exposure. Biological 
reference values represent biological levels that would be observed in fluids collected in healthy 
workers repeatedly exposed at a given reference air concentration. It can thus be expected that, 
due to age, different values would be observed. Table 3 presents levels that would be observed in 
65 years old workers, taking young workers as reference. This information could be used to 
improve our interpretation of biological monitoring results, unless better information is available. 
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Table 3 Predicted biological reference values in 65 years old workers 
Chemical/ Sampling Corresponding BEI(2) VEI(3) Simulated Simulated Expected 
biological indicator time(1) exposure level     
value   
Age 25 
value   
Age 65 
change [%]   
Age 65 vs Age 25
Arsenic   0.01 mg/m3           
inorganic arsenic and its 
metabolites in urine EW   35 g As/l 14.2-66.9 63.7 84.2 32 
Cadmium  0.01 mg/m3           
cadmium in urine NC   
5 g/g 
creatinine 1.6-14.9 4.7 5.6 19 
cadmium in blood NC   5 g/l 3.8-6.5 1.2 1.7 42 
Chromium (VI)  0.05 mg/m3           
chromium in urine ESW   25 g/l 15.4-72.3 43.9 51.9 18 
Cobalt  0.02 mg/m3           
cobalt in urine ESW   15 g/l 4.7-17.9 10.4 9.8 -6 
cobalt in blood ESW   1 g/l 0.59-1.18 0.85 0.92 8 
2-Ethoxyethanol  5 ppm           
2-ethoxyacetic acid in urine ESW   
100 mg/g 
creatinine 41.5-244.1 68.7 94.1 37 
Ethylbenzene  100 ppm           
mandelic acid in urine ESW   
0.7 g/g 
creatinine 0.6-3.8 1.6 1.8 13 
Fluorides  2.5 mg/m3           
fluorides in urine PS   
3 mg/g 
creatinine 1.2-7.9 3.4 3.5 3 
fluorides in urine ES   
10 mg/g 
creatinine 4.5-22.4 9.4 10.6 13 
Lead  0.05 mg/m3           
lead in blood NC   300 g/l 161.2-561.6 188.5 217.6 15 
Mercury (inorganic)  0.025 mg/m3           
mercury in urine PS   
35 g/g 
creatinine 10.6-113.6 30.8 35.1 14 
mercury in blood ESW   15 g/l 9.2-25.1 13.6 16.7 23 
Methylisobutylketone  50 ppm           
methylisobutylketone in urine ES   2 mg/l 0.8-5 4.1 6.1 49 
Pentachlorophenol  0.5 mg/m3           
conjugated pentachlorophenol in urine PSW   
2 mg/g 
creatinine 0.9-4.2 1.8 2.1 17 
pentachlorophenol in blood ES 5 mg/l 2.7-10.1 3.7 4.7 27
Phenol  5 ppm           
phenol in urine ES   
250 mg/g 
creatinine 97.4-511.4 327.9 402.1 23 
Toluene  20 ppm           
o-cresol in urine ES   0.5 mg/l 0.16-1.53 0.98 1.09 11 
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(1) Time of sampling: ES = end of shift; EW = end of workweek; ESW = end of shift at end of workweek; NC 
= not critical; PS = prior to shift; PSW = prior to last shift of the workweek 
(2) BEI = biological exposure indices (ACGIH® 2007) 
(3) VEI = variability extent index with the 95% limit values (Truchon et al. 2006)  
  
Discussion 
The TK model used here is relatively simple and do not represent each chemical’s specific detail. 
More elaborated techniques, such as PBPK models, could give a better view of the effect of age. 
However it would be more difficult to develop a general model for a category of chemicals 
describing the differences due to age. 
The present results indicate that the influence of age is chemical specific. Some chemicals seem 
to be hardly affected while others show large differences. The same is indeed true when 
considering biological indicators of exposure.  
For chemicals in blood, differences can be important due for example to the presence of a 
peripheral compartment in the toxicokinetic model. Changes due to age like the lean body 
fraction, the kidney fraction or the liver fraction of bodyweight could explain an increase in the 
blood concentration of a substance. When the peripheral compartment is represented by the 
volume of body fat, differences are not so important. Changes in body mass, or more specifically 
in total body water and body fat, will have an influence on the distribution volumes of a 
chemical. The consequence can be an increased concentration of hydrophilic substances and a 
prolonged half-life for a lipophilic substance. Products with a fast metabolism seem to have a 
little impact with age on the blood concentration. In the case of the concentration in the 
peripheral compartment, it seems to increase with age when the target organ is represented by the 
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liver or the kidneys. When looking at the differences due to age for the metabolic and excretion 
compartment, it is evident that for several chemicals, the elimination parameters as the excretion 
rate have a significant impact on the concentrations. In very few cases, there is a decrease in the 
urinary concentration of the substance when the aged person is compared to the younger one, 
which could be explained by the interindividual variablity. Thus it seems difficult to set up 
simple rules for a category of chemicals, each chemical being a specific case which has to be 
investigated by its own. Parameters as metabolism, storage, long half-lives, hydrophilic or 
lipophilic property of a chemical are often chemical-specific. It is not evident to do some 
classification like organic and inorganic products, or lipophilic and hydrophilic substances 
because in both cases important and less important differences exist.  
In this context, toxicokinetic models seem to be appropriate tools. It is therefore essential to study 
and describe not only some specific chemicals, but also the mechanism underlying those changes 
in order to be able to forecast changes for new chemicals.  
When compared to global biological variability expected in workers (Lin et al. 2005; Truchon et 
al. 2006) which is about 30 %, the tentative predictions made here indicate that age could be in 
some cases an important determinant of variability. The variability extent index estimated by 
Truchon et al. (2006) which had not taken into account variability due to age, show that in some 
cases, the simulated value of a 65-year old worker can be out of the estimated interval of values. 
It is also interesting to notice that in several cases the simulated values exceed the biological 
exposure indices. In very few cases, there is a decrease in the urinary concentration of the 
substance when the aged person is compared to the younger one. Predictions of age differences in 
biological indicators were made based on typical values for specific physiological and metabolic 
parameters. Further work should be done to improve our estimates of these parameters and in 
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consequence their influence. Notably uncertainty and variability in these parameters could be 
considered, using for example Monte-Carlo simulations. Further studies, like human volunteer 
exposure, need to be done to reach a better quantitative description of age differences in 
biological monitoring results. 
Furthermore the present predictions do not take into account the apparition of various diseases 
with age and the increase use of medications. These aspects would probably enhance differences. 
The present predictions should therefore be considered as minima to be expected. 
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 3.2. Paper II 
 
Sensitive headspace gas chromatography analysis of free and conjugated 1-methoxy-2-
propanol in urine 
 
Catherine Tomicic1 and Michèle Berode1 
1 Institute for Work and Health, University of Lausanne, 1011 Lausanne, Switzerland 
 
Abstract 
 
Glycol ethers still continue to be a workplace hazard due to their important use on an industrial 
scale. Currently, chronic occupational exposures to low levels of xenobiotics become 
increasingly relevant. Thus, sensitive analytical methods for detecting biomarkers of exposure are 
of interest in the field of occupational exposure assessment.  
1-Methoxy-2-propanol (1M2P) is one of the dominant glycol ethers and the unmetabolized 
urinary fraction has been identified to be a good biological indicator of exposure. An existing 
analytical method including a solid-phase extraction and derivatization before GC/FID analysis is 
available but presents some disadvantages.  
We present here an alternative method for the determination of urinary 1M2P based on the 
headspace gas chromatography technique. We determined the 1M2P values by the direct 
headspace method for 47 samples that had previously been assayed by the solid-phase extraction 
and derivatization gas chromatography procedure. An intermethod comparison based on a Bland-
Altman analysis showed that both techniques can be used interchangeably. The alternative 
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method showed a tenfold lower limit of detection (0.1 mg/L) as well as good accuracy and 
precision which were determined by several urinary 1M2P analyses carried out on a series of 
urine samples obtained from a human volunteer study. The within- and between-run precisions 
were generally about 10 %, which corresponds to the usual injection variability. 
We observed that the differences between the results obtained with both methods are not 
clinically relevant in comparison to the current biological exposure index of urinary 1M2P. 
Accordingly, the headspace gas chromatography technique turned out to be a more sensitive, 
accurate and simple method for the determination of urinary 1M2P.  
  
Keywords:  Biological monitoring - 1-Methoxy-2-propanol - Headspace gas chromatography 
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1.  Introduction  
Since the 1970s, glycol ethers represent an interesting solvent family for industrial use due to 
their amphiphile behavior. They can be classified into two groups: ethylene glycol ethers (EGE) 
and propylene glycol ethers (PGE). Glycol ethers from the ethylenic series were used on a large 
scale until their reprotoxicity was discovered [1;2]. During the last twenty years, a huge work of 
substitution took place by proposing glycol ethers from the propylenic series. The main 
difference between these two groups of chemicals lies in their way of biotransformation (see [3] 
for a good review of the metabolism and the disposition of glycol ethers).  
In humans, EGE are first transformed into 2-alkoxy acetaldehydes by alcohol deshydrogenases, 
and then into alkoxyacetic acids by aldehyde deshydrogenases, which are metabolites considered 
responsible for toxicities. PGE exist under the form of two isomers, [4] alpha-isomer and beta-
isomer. Alpha-PGE are primarily metabolized through microsomal o-demethylation yielding to 
relatively non-toxic metabolites of propylene glycol, carbon dioxide and glucuronide as well as 
sulfate conjugates of the parent compound. In contrast, the beta-isomer, because it is a primary 
alcohol, is an excellent substrate for alcohol dehydrogenase. Metabolism of the beta-isomer is 
thus similar to that observed for the ethylene glycol ether series.  
1-Methoxy-2-propanol (1M2P), the shorter compound from the propylenic series, is used in a 
wide variety of industrial and commercial products, primarily water-based paints, varnishes and 
inks [5-7]. Commercial grade 1M2P is a mixture of two isomers: the major form being the alpha-
isomer 1M2P and the minor form being the beta-isomer 2-methoxy-1-propanol, which is 
considered as an impurity. 
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In spite of some work [8;9] showing the validity of urinary alkoxypropionic acids as biomarker 
of 1M2P exposure, the need to analyse unmetabolized 1M2P in urine as free or conjugated 
products is also becoming more interesting for the exposure assessment [10;11;12], since the 
conjugated 1M2P fraction appeared to be between 30% and 65% [4]. Moreover, different 
countries have published a biological exposure index for urinary 1M2P at the end of the work 
shift, fixed at 15 mg/L by the German Research Foundation [13] and 20 mg/L by the Swiss 
National Accident Insurance Fund [14]. 
In the frame of a planned study on mice exposed to 1M2P vapors (unpublished results), our 
former method [4] has been first modified and then replaced because of its low sensitivity due to 
small volumes of biological fluids. Thus, there is an obvious need to develop a sensitive, reliable 
and alternative method.  
In this study, a GC headspace injection method is proposed to quantify free and conjugated 1M2P 
in urine. This analytical method has also been compared to the previous solid-phase extraction-
derivatization GC procedure [4] by quantifying urinary 1M2P in about forty samples of 
volunteers exposed to 1M2P using both methodologies. Lastly, our analytical method was 
validated and applied to the analysis of urine samples collected from volunteers exposed to 
1M2P. 
 
2.  Experimental 
 
2.1 Chemicals and standards preparation 
1M2P (> 98%) as analytical standard was obtained from Sigma-Aldrich (Buchs, Switzerland) and 
tert-butoxy-2-propanol as internal standard (IS) from Fluka (Buchs, Switzerland). All other 
 69 
 
products, anhydrous sodium sulfate, hydrochloric acid and sodium hydroxide were obtained from 
Merck (Darmstadt, Germany) and were used without further purification. Water was purified 
through a Millipore treatment system. 
The primary stock solutions were prepared by dilution of 50 µl of the commercial product in 50 
mL of deionized water to obtain respective concentrations of 0.921 mg/mL for M2P and about 1 
mg/mL for tert-butoxy-2-propanol used as internal standard.  
Working standard of 1M2P (18.42 µg/mL) was prepared by dilution of 1.0 mL of the stock 
solution to 50 mL of deionized water. For the internal standard, the working solution is diluted 50 
fold in deionized water. The stock solutions were kept between 5°C and 8°C and were stable for 
at least one month. Working solutions were freshly prepared every day.  
 
2.2 Equipment 
The apparatus used for the urine analysis was an Agilent 6890 gas chromatograph (Agilent 
Technologies AG, Urdorf, Switzerland) equipped with a Gerstel Multipurpose Sampler (Gerstel 
AG, Sursee, Switzerland) operated in headspace mode and with a 2.5 mL tight gas syringe.  
The separation was performed on a CP-Sil 8 CB capillary column (95% dimethylpolysiloxane 
polymer, 5% phenyl groups; 60 m x 0.25 mm i.d., 0.25 m film thickness, Varian Chrompack 
(Milian SA, Geneva, Switzerland)) using nitrogen as a carrier gas at a constant flow rate of 1.5 
mL/min. The oven temperature was initially held at 90°C during 8 minutes, then increased to 
250°C at 20°C/min and held for 2 minutes. The injector temperature was set at 250 °C and 
injection was performed with a split ratio of 10:1. The flame ionization detector was set at 250°C 
with an air flow rate of 300 mL/min, hydrogen flow rate of 30 mL/min and a nitrogen makeup 
flow rate of 30 mL/min. 
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The urine sample was kept at a temperature of 95°C during 60 minutes in the agitator of the 
Multipurpose Sampler. The incubation of the samples was performed automatically in the 
headspace mode, with a correct throughput as the agitator has 6 positions. The syringe 
temperature was 80°C and the injected sample volume was 1000 µl. 
The retention times in these conditions were 6.81 minutes for 1M2P and 11.60 minutes for the 
internal standard.  
 
2.3 Calibration and urine samples preparation  
A set of seven 1M2P calibration points was prepared at the 0, 2.30¸ 4.61, 6.91, 9.21, 13.82 and 
18.42 mg/L levels in water by direct addition in a 20 mL headspace flask containing 6 g of 
Na2SO4 of 0, 250, 500, 750, 1000, 1500 and 2000 µl of the 1M2P working standard solution.  
The final volume was then adjusted to 2 mL with deionized water. After the addition of 100 µl of 
the internal standard working solution, the vials were capped.  
Two milliliters of human urine and 100 µl of internal standard solution were transferred to the 20 
mL headspace vial, screw top, containing 6 g of Na2SO4. The vial was rapidly sealed with a 
PTFE-septum magnetic screw cap. 
To determine the quantity of conjugated 1M2P, an acidic hydrolysis was realized on each urine 
sample. After the preparation of the calibration points and the samples by the same procedure as 
above, 200 µl of 10M hydrochloric acid were added to each specimen. Tubes were capped, mixed 
and incubated at 100°C for 16 hours. After allowing specimens to cool to room temperature, the 
reaction medium was neutralized by addition of 200 µl of 10M sodium hydroxide. The vials were 
capped and then ready for the analysis. 
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The difference in volume (400 µL) between the samples without hydrolysis and those with 
hydrolysis was insignificant in comparison to the volume of the headspace vial (20 mL). 
Moreover, the matrix effect was not relevant due to the addition of a large amount of salt.  
 
2.4 Internal quality control 
For assessment of assay precision, urine pools were prepared at two concentrations levels: 1.5 
mg/L and 2.9 mg/L for the samples without hydrolysis process and 1.7 mg/L and 4.9 mg/L for 
the samples with hydrolysis process. They were aliquoted and stored at –20°C until used to assay. 
 
3. Results 
 
3.1 Effect of salt addition 
As recommended since 1981 by Sedivec [15] and largely experimented by our team for alcohol 
determination in urinary samples [16], the addition of a saturating amount (6 g) of Na2SO4 has an 
important effect on the partition coefficient of an alcohol. A single experiment has been carried 
out, comparing a double set of five 1M2P calibration points without salt to another one with salt. 
In fact, as illustrated in Fig. 1, the salt addition induced a major increase of the chromatographic 
signal of compounds of interest with a mean improvement of 7.9±0.4 times for 1M2P and for IS. 
Based on these facts, analysis was performed with salt addition. 
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Fig. 1 Effect of addition of saturating amount (6 g) of Na2SO4 on spiked urine samples 
(calibration points) on the chromatographic response of 1M2P at different levels and on the 
signal of tert-butoxy-2-propanol used as internal standard (IS).  
 
3.2 Hydrolysis conditions 
While acidic hydrolysis temperature was kept as in the former method [4], the hydrolysis time 
has been increased. Indeed, the 1M2P peak height after 10 hours is nearly a third time higher than 
the one obtained after 2 hours of incubation. Samples were thus kept at 100°C overnight.     
In comparison to the analyte, the internal standard has to be a non-endogenous structural 
analogue and preferably of low toxicity. Tert-butoxy-2-propanol has been identified as the most 
appropriate internal standard for the method in question. However, the tert-butyl group is easily 
cleaved off under strongly acidic conditions, particularly if heated, and for this reason, the IS has 
been added after hydrolysis.  
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3.3 Method-to-method comparison 
For method comparison, we determined the urinary 1M2P values by the method proposed here 
for 47 samples that had previously been assayed by GLC method [4] and stored at –20°C in the 
meantime. One alternative allowing to affirm if two methods can be used interchangeably or if 
the new method can replace the existing one is the methodology proposed by Altman and Bland 
[17]. The Bland-Altman method permits in our case to determine consistency between two sets of 
measurements, which are here the urinary 1M2P concentrations obtained for 47 samples by two 
different methods [18]. The first step consisted to construct a scatter plot using the direct 
headspace method (GC-HS method) vs gas chromatography with liquid injection method after 
solid-phase extraction and derivatization (GLC method), with the line of perfect correlation 
superimposed (y=x). The results are illustrated in Fig. 2 for the urinary 1M2P concentrations 
determined without hydrolysis only, as the results are similar when hydrolysis takes place.  
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Fig. 2 Scatter plot of 1M2P concentrations (C1M2P) determined without hydrolysis using the direct 
headspace method (GC-HS method) vs gas-chromatography with liquid injection method after 
solid-phase extraction and derivatization (GLC method [4]), with the line of perfect correlation 
superimposed (y=x) represented by dotted lines  
 
A high correlation does not automatically imply that there is good agreement between the two 
methods. For this reason, the Altman and Bland methodology proposes to plot a graph by 
assigning the mean of the two measurements as the abscissa (x-axis) value, and the difference 
between the two values as the ordinate (y-axis) value. The Bland-Altman plots are represented on 
Fig. 3, with the limits of agreement represented by dotted lines (mean difference between the two 
methods ± 2 standard deviations of the differences). The results illustrated in Fig. 3 correspond to 
the urinary 1M2P concentrations determined without hydrolysis only, as the results are similar 
when hydrolysis takes place.  
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Fig. 3 Plot of difference vs mean (Bland-Altman plots) of 1M2P concentrations (C1M2P) 
determined without hydrolysis using the direct headspace method (GC-HS method) and gas-
chromatography with liquid injection method after solid-phase extraction and derivatization 
(GLC method [4]), with the limits of agreement represented by dotted lines (mean difference 
between the two methods ± 2 standard deviation of the differences) 
 
3.4 Linearity, limit of detection, within- and between-run precision, accuracy 
Calibration standards were prepared and analyzed in duplicate in five independent runs. The 
calibration curve was constructed using 1M2P/IS peak height ratios vs 1M2P concentration at 
seven levels in the range 0 to 20 µg/l. The calibration curves were linear over the entire 
investigated range with a correlation coefficient typically above 0.99. The analytical limit of 
detection (LOD) was 0.1 mg/L estimated from repeated analysis of blank specimens. 
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A low and a high value for the calibration on one hand and for the internal controls on the other 
hand have been chosen to represent within- and between-run precision, generally about 10 % 
which corresponds to the usual injection variability, and accuracy (99.7-106.4 %) for the 
determination of urinary 1M2P concentrations. The results are summarized in Tables 1 and 2, 
without and with hydrolysis process respectively. 
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Table 1 Determination of free urinary 1M2P by the headspace GC technique: accuracy, within-
run and between-run precisions; they are represented by several 1M2P analyses carried out on a 
low and a high value of 1M2P, for the calibration on one hand and for the internal controls on the 
other hand. 
 
    1M2P theoretical concentrations  
               Calibration points                 Internal controls 
  2.0 [mg/L] 10.0 [mg/L] 1.5 [mg/L] 2.9 [mg/L]
Run 1 Mean (N=4) 2.185 10.038 1.438 2.993
 CV%* 1.8 5.0 10.5 8.1 
 % Theoretical 109.3 100.4 98.5 103.2 
Run 2 Mean (N=4) 2.342 10.067 1.435 2.935
 CV%* 6.4 2.8 9.1 2.3 
 % Theoretical 117.1 100.7 98.3 101.2 
Run 3 Mean (N=4) 2.061 10.081 1.660 2.988
 CV%* 15.6 3.4 7.4 10.3 
 % Theoretical 103.1 100.8 113.7 103.0 
Run 4 Mean (N=4) 1.920 10.100 1.288 2.693
 CV%* 8.8 14.0 8.7 14.7 
 % Theoretical 96.0 101.0 88.2 92.8 
Overall Mean (N=16) 2.127 10.0.71 1.455 2.902
 CV%** 11.2 7.0 12.4 9.7 
 % Theoretical*** 106.4 100.7 99.7 100.1 
 
with  N = number of samples 
 CV = coefficient of variation  
 
*  Within-run precision 
**  Between-run precision 
***  Accuracy 
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Table 2 Determination of total urinary 1M2P by the headspace GC technique: accuracy, within-
run and between-run precisions; they are represented by several 1M2P analyses carried out on a 
low and a high value of 1M2P, for the calibration on one hand and for the internal controls on the 
other hand. 
 
  1M2P theoretical concentration  
              Calibration points                              Internal controls  
  2.0 [mg/L] 10.0 [mg/L] 1.7 [mg/L]  4.9 [mg/L]
Run 1 Mean (N=4) 1.790 10.186 1.533  4.613 
 CV%* 5.1 4.9 6.3  1.5 
 % Theoretical 89.5 101.9 90.1  94.9 
Run 2 Mean (N=4) 2.066 10.544 1.675  5.063 
 CV%* 12.7 7.8 7.5  5.2 
 % Theoretical 103.3 105.4 98.5  104.2 
Run 3 Mean (N=4) 1.955 10.192 1.728  4.873 
 CV%* 10.4 7.4 10.8  10.1 
 % Theoretical 97.7 101.9 101.6  100.3 
Run 4 Mean (N=4) 2.209 10.712 1.845  4.873 
 CV%* 8.2 11.1 6.6  12.3 
 % Theoretical 110.5 107.1 108.5  100.3 
Overall Mean (N=16) 2.005 10.409 1.695  4.855 
 CV%** 11.7 7.7 10.0  8.3 
 % Theoretical*** 100.2 104.1 99.7  99.9 
 
with  N = number of samples 
 CV = coefficient of variation  
 
*  Within-run precision 
**  Between-run precision 
***  Accuracy 
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4. Discussion 
 
The results of our study suggest that urinary 1M2P can be quantified by a GC headspace injection 
method, which is especially useful for the assessment of low occupational exposure levels.  
For 1M2P, with a vapor pressure of 12 mmHg (1.60kPa), the headspace technique, as applied to 
different organic volatiles [15], should be suitable to extract this methoxy alcohol derivative from 
biological fluid.. 
In comparison to the existing analytical method [4], several aspects have been improved. The 
influence of the salt addition on the partition coefficients in gas-water systems with the 
enrichment of compounds of interest in the “head space” phase is a crucial factor in improving 
the sensitivity of analysis. The LOD obtained in the described conditions were much lower (10 
fold better) than those obtained with the existing method for the determination of urinary 1M2P 
including a solid-phase extraction and derivatization before GC/FID analysis. With a LOD of 0.1 
mg/L, the GC headspace technique allows to determine the target substance in small volumes of 
biological fluids and/or in low occupational exposures situations.  
The method-to-method comparison shows on one hand that the correlation between the measured 
1M2P values by both methods seems to be better for the low values as for the higher ones. The 
fact that there are more samples for the lower values can partly explain this observation. On the 
other hand, the difference against mean diagram shows that generally, the values are slightly 
higher for the liquid injection method as for the GC headspace technique. As a good stability of 
the analyte has been demonstrated by [11] and as the sample preparation is a simple procedure, 
the important difference in sensitivity of both methods could explain the observed variability in 
the measurement. 
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The Bland-Altman plots show that 95% of the differences obtained between both analytical 
methods fall within the limits of agreement. Furthermore, we can assume that these differences 
are not clinically relevant in comparison to the usual biological exposure indices of urinary 
1M2P. Thus both methods can be used interchangeably.  
The precision of the method, calculated as intra- and inter-day reproducibility, was generally 
about 10 %, which corresponds to the usual injection variability. The difference between 
theoretical concentration values and the measured one shows a high accuracy. Consequently, the 
important criteria for the validation of an analytical method are fulfilled.  
Another advantage concerns the sample preparation, an uncomplex and short procedure thus 
limiting possible sources of errors due to manipulation.  
Some limitations of the method exist: it is necessary to avoid the contamination of the urine 
samples by surrounding solvents or the loss of the analyte during manipulation and analysis.  
In summary, we conclude that the determination of urinary 1M2P by the headspace technique is a 
high sensitive and a particularly simple analytical method, useful in the assessment of low 
occupational exposure levels to 1M2P. The analytical procedure could be adapted for the 
determination of other substances of the glycol ethers family as long as physico-chemical 
properties allow it. 
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Abstract 
The aim of the study was to quantify the variability on biological indicators of exposure between 
men and women for three well known solvents: methyl ethyl ketone, 1-methoxy-2-propanol and 
1,1,1-trichloroethane. Another purpose was to explore the effect of selected CYP2E1 
polymorphisms on the toxicokinetic profile. 
Controlled human exposures were carried out in a 12 m3 exposure chamber for each solvent 
separately, during 6 hours and at half of the threshold limit value. The human volunteers groups 
were composed of ten young men and fifteen young women, including ten women using 
hormonal contraceptive.  
An analysis of variance mainly showed an effect on the urinary levels of several biomarkers of 
exposure among women due to the use of hormonal contraceptive, with an increase of more than 
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50 % in metabolites concentrations and a decrease of up to 50 % in unchanged substances 
concentrations, suggesting an increase in their metabolism rate. The results also showed a 
difference due to the genotype CYP2E1*6, when exposed to methyl ethyl ketone, with a 
tendency to increase CYP2E1 activity when volunteers were carriers of the mutant allele. 
Our study suggests that not only physiological differences between men and women but also 
differences due to sex hormones levels can have an impact on urinary concentrations of several 
biomarkers of exposure. The observed variability due to sex among biological exposure indices 
can lead to misinterpretation of biomonitoring results. This aspect should have its place in the 
approaches for setting limits of occupational exposure. 
 
Keywords:  Human biomonitoring – Biological indicators of exposure – Sex differences – 
Toxicokinetics – Organic solvents 
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1. Introduction 
Due to their chemical properties, organic solvents are commonly used worldwide in different 
industrial sectors as degreasing and diluting agents. They can be mainly classified as aliphatic 
hydrocarbons, cyclic hydrocarbons, aromatic hydrocarbons, halogenated hydrocarbons, ketones, 
amines, esters, alcohols, aldehydes, ethers and glycol ethers. Their production and use increased 
mainly in the latter half of the 19th century due to the coal-tar industry.  
During the 1980's, a major concern for occupational hygienists and physicians was the risk 
assessment of occupational exposure to volatile organic compounds (Droz et al., 1983) as their 
neurotoxicity represented one of the most important emerging issues in the field of occupational 
health (Baker 1988). 
Biological monitoring is a widely used method in the assessment of occupational exposure. It 
often relies on measurements of the chemical or its metabolites in biological fluids, identified as 
biomarkers of exposure. Recommended biological limits for chemical substances, most based on 
a direct correlation with the corresponding threshold limit values, are published periodically in 
Switzerland and in other countries for interpretation and decision-making.  
Recently, much more attention has been devoted to variability associated with biological 
monitoring results (Tardif et al., 2002; Pierrehumbert et al., 2002; Truchon et al., 2006; Thomson 
et al., 2010).  Several studies in volunteers and with toxicokinetic models have now shown that 
biological results follow approximatively log-normal distributions, characterized by geometric 
standard deviations ranging from about 1.3 to 2.0 (Droz, 1992), equivalent to a coefficient of 
variation between 30 % and 100 %. This large biological variability was already obvious to drug 
therapists (Meibohm et al., 2002; Schwartz, 2003), and adaptation of dosage is normal current 
practice, at least for drugs with narrow therapeutic ranges.  
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Among others, sex is an easily identifiable determinant which could provide an important 
contribution to biological variability. The influence of sex on toxicokinetics may involve female-
male differences in physical constitution (body water space, muscle mass, body fat, and blood 
flow), physiology (menopause and menstruation cycle), hormones (contraceptive pill) and 
metabolising enzymes (Löf et al., 1998). Lipophilic substances will tend to have a greater 
distribution volume in women, hydrophilic substances will show the opposite (Schwartz, 2003). 
The binding in plasma to proteins is also influenced by sex hormones, which can lead to 
toxicokinetic differences (Gandhi et al., 2004). Cytochrome P450 dependent mono-oxygenases 
are the most prominent enzymes involved in solvent metabolism. Isoenzymes belonging to the 
first four gene families (CYP 1-4) are involved in the metabolism of xenobiotics (Löf et al., 
1998). The metabolism of many solvents includes oxidation by the CYP2E1 (Nakajima et al., 
1997). This specific isoform, probably among others, is known to exhibit sex differences and to 
show a polymorphism (Bebia et al, 2004).  
There are only a few studies evaluating possible sex differences in the toxicokinetics of 
occupational chemicals in humans. Swedish researchers exposed male and female volunteers to 
m-xylene and 2-propanol under controlled conditions (Ernstgård et al., 2003a,b) and found 
toxicokinetic modifications for both chemicals, which they attributed mainly to anatomical 
differences between sexes. Small changes in acute health effects were also identified in these 
experiments (Ernstgård et al, 2002).  
Although one can establish a list of contributing factors (Gochfeld, 2007), their relative 
importance for different chemicals of occupational interest is unknown. Several authors recently 
recommended that more toxicokinetic studies be undertaken to better characterize the influence 
of sex (Arbuckle, 2006; Messing, 2006). 
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The main objective of this study was therefore to quantify the variability on biological indicators 
of exposure between men and women for three well known solvents, which are methyl ethyl 
ketone, 1-methoxy-2-propanol and 1,1,1-trichloroethane. Another purpose was to explore the 
effect of selected CYP2E1 polymorphisms on the toxicokinetic profile. Some of the results of this 
study have been previously reported in the form of an abstract (Tomicic et al., 2010). 
 
2. Material and methods 
 
2.1. Human volunteers 
The experimental protocol was approved by the Clinical Research Ethics Committee of the 
Faculty of Biology and Medicine at the University of Lausanne, according to the Declaration of 
Helsinki.  
Ten men and fifteen women participated in the study. Each volunteer had to undergo a medical 
examination including a health questionnaire, a general physical examination, standard clinical 
blood and urine analyses, an electrocardiogram and a spirometry. Body fat was measured the day 
of exposure with a body fat monitor using bioelectric impedance (Omron BF 300, Omron 
Healthcare Europe).  
The  following inclusion criteria were used to select the participants: caucasian, age between 20 
and 25 years, body mass index between 18 and 28, non-smoker, no history of chronic or allergy 
disease, no occupational exposure to organic solvents, no chronic use of drugs and no pregnancy.  
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2.2. Chemicals 
Three chemicals have been selected for their relatively low toxicity as well as their metabolic and 
physiological properties: methyl ethyl ketone (MEK), watersoluble and highly metabolized, 1-
methoxy-2-propanol (1M2P), amphiphile and highly metabolized, and 1,1,1-trichloroethane, 
liposoluble and poorly metabolized.  
MEK (> 99.5 %) and 1M2P (> 98 %) were obtained from Sigma-Aldrich (Buchs, Switzerland) 
and 111TCE (> 99.5 %) from Merck (VWR International AG, Schlieren, Switzerland). 
The three solvents are mainly absorbed by inhalation and metabolized via the cytochrome P450 
mixed-function oxidase system. 
MEK is metabolized to 2,3-butanediol, 2-butanol and 3-hydroxy-2-butanone (major metabolite), 
all excreted in urine. A low fraction of unchanged solvent is excreted in the exhaled air and in 
urine. The urinary concentration of MEK at the end of the shift has been recommended as the 
most appropriate biological exposure indicator. 
1M2P belongs to the family of the propylene glycol ethers (PGE) which exists under the form of 
two isomers, alpha-isomer and beta-isomer. The latter one, considered as an impurity in 
commercial use, is first transformed as all primary alcohols into 2-alkoxy acetaldehydes by 
alcohol deshydrogenases, and then into alkoxyacetic acids by aldehyde deshydrogenases, a toxic 
metabolite. Alpha-PGE are primarily metabolized to propylene glycol, carbon dioxide and 
glucuronide as well as sulfate conjugates of the parent compound. The urinary 1M2P 
concentration at the end of the shift corresponds as the appropriate biomarker. 
1,1,1-trichloroethane is metabolised to trichloroethanol (TCE) and trichloroacetic acid (TCA), 
both excreted in urine. Other minor metabolites (carbon dioxide, acetylene) are excreted in the 
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exhaled air. The corresponding biological exposure indices are the urinary concentration of both 
metabolites and the blood concentration of the parent compound. The 111TCE concentration in 
the exhaled air can also be considered as a biomarker of exposure. 
Table 1 summarizes useful information about existing threshold limit values and biological 
exposure indices regarding the biological determinants corresponding to the three studied organic 
solvents.  
 
Table 1. Summary of the selected organic solvents with occupational exposure limits (OELs in ambient air) and 
corresponding biomarkers of exposure,for different countries (USA, Germany, Switzerland) 
  BEI*/BAT**/VBT*** 
Biological determinant TLV*/MAK**/VME***  urine blood expired air 
  (ppm)  (mg/l) g/l) (ppm) 
Methyl ethyl ketone (MEK) 200/200/200 2/5/5 (ESa)  - -  
          
1-Methoxy-2-propanol (1M2P) 100/100/100 -/15/20 (ES)  - -  
          
1,1,1-Trichloroethane (111TCE) 350/200/200  -  -/550/550 (PSc, EW) 40/-/- (PS, EW) 
Trichloroethanol (TCE)   30/-/- (ES, EWb) -               - 
Trichloroacetic acid (TCA)   10/-/- (EW) -  -  
 
*  The American Conference of Industrial Hygienists (ACGIH) sets threshold limit values (TLV) and biological exposure 
indices (BEI). 
**  The German Research Foundation (Deutsche Forschungsgemeinschaft - DFG) sets “Maximale Arbeitsplatz-
Konzentrationen”  (MAK) and “Biologische Arbeitsstoff-Toleranzen” (BAT). 
*** The Swiss National Accident Insurance Fund (Schweizerische Unfallversicherungsanstalt - Caisse nationale suisse 
d'assurance en cas d'accidents - Istituto nazionale svizzero di assicurazione contro gli infortuni - SUVA) sets “valeurs 
(limites) moyennes d’exposition” (VME) and “valeurs biologiques tolérables” (VBT). 
 
a ES: end of shift  b EW: end of week  c PS: prior to shift 
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2.3. Exposure conditions and experimental design 
The experiments were carried out in a 12 m3 air-conditioned exposure chamber and were 
conducted over 37 separate sessions. The chamber allows the simultaneous exposure of three 
volunteers to vapors. The responsible physician’s main duties were to check the participant 
before exposure, to make sure that inclusion criteria were still respected, and to see the volunteer 
after and the day following exposure to assess any health outcome due to the exposure session. 
Exposures lasted for 6 hours at rest, at half of the threshold limit value of the used solvent. The 
intended exposure levels were based on the Swiss OELs and corresponded to 100 ppm for MEK 
and 111TCE, and to 50 ppm for 1M2P. Each volunteer was separately exposed to the three 
solvents, with a minimum of two weeks (based on a 100 hr half-time) between 2 exposure 
scenarios to avoid cross-cumulation. The temperature in the chamber was maintained at about 24 
°C and the air renewal was between 12 and 15 per hour. A peristaltic pump pushed the solvent to 
a heated aluminium plate (kept at a temperature about 10 °C above the boiling point of the 
considered solvent) where it evaporated to be immediately injected into the ventilation of the 
chamber. The solvent generation was controlled by the LabVIEW software (National Instruments 
Corporation, Texas, USA). 
 
2.4. Air monitoring 
The solvent concentration in the chamber was continuously monitored by two independent 
methods: a portable FTIR (Fourier Transform Infrared Spectroscopy) gas analyzer for ambient air 
analysis (Gasmet™ DX4015, Gasmet Technologies Oy, Helsinki, Finland) and a Perkin Elmer 
gas chromatograph (GC), with a flame ionization detector (FID), connected to a Hewlett Packard 
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3395 integrator. With the latter one, a measurement was taken every half an hour. Solvent 
concentration in the exposure chamber was additionally assessed by active personal air sampling. 
Solvents were collected on tubes containing activated charcoal as adsorbent, with air samplings 
rates of 40 ml/min. After desorption with carbon disulfide (in the case of MEK and 111TCE) or 
dichloromethane (in the case of 1M2P), analysis were done by GC using a flame ionization 
detector. 
 
2.5. Biological monitoring 
Sampling: Urine samples were collected before, during (with a predefined timing and in a 
solvent-free area) and after (collected ad lib) exposure. The samples were kept in polyethylene 
bottles or in brown borosilicate flasks directly after reception and stored refrigerated at 4 °C. 
When kept in polyethylene bottles, samples were aliquoted and stored frozen (-20 °C) at the end 
of the exposure session. Blood samples were taken before and after the exposure, as well as 
during the following day when the volunteers came back to bring the urine samples. Venous 
blood was collected in 9-ml vacuum tubes with an anticoagulant comprising 
ethylenediaminetetraacetic acid (EDTA) and stored in a refrigerator at 4 °C until analysis. 
Expired air was sampled immediately after the exposure by taking at least 3 points during the 
hour following the exposure. 
Analytical methods: Analytical methods for exposure measurements and biological 
determinations in urine, blood and expired air are mostly under control at the Institute for Work 
and Health (IST) in Lausanne, Switzerland, in an ISO 17025 certification scheme. Parent 
compounds and metabolites have been analysed by gas chromatography according to published 
schemes. The determination of all the defined biomarkers of exposure was based on the 
 92 
 
headspace gas chromatography technique. As recommended since 1981 by Sedivec et al. (1981) 
and largely experimented by our team for alcohol determination in urinary samples (Sethre et al., 
2000), the addition of a saturating amount of Na2SO4 has an important effect on the partition 
coefficient of solvents, in our case of MEK and 1M2P. An existing analytical method for the 
determination of urinary 1M2P including a solid-phase extraction and derivatization before 
analysis is available (Devanthéry et al., 2000) but presents some disadvantages. In the frame of 
this study, an alternative method based on the headspace gas chromatography technique has been 
developed (Tomicic et al., 2010). The quantity of conjugated 1M2P has been determined after an 
acidic hydrolysis, realized by adding hydrochloric acid to the samples and by keeping them at 
100°C overnight. 
Regarding the 111TCE metabolites, urinary TCE and urinary TCA have been analysed after 
methylation, transforming TCA to its corresponding and more volatile ester, and after hydrolysis, 
in order to assess total TCE as it can be present under its conjugated form (Breimer et al., 1974). 
As recommended for spot urine specimen, creatinine adjustment was performed for each sample 
to correct for urine dilution. Creatinine concentration was determined by a modified Jaffe 
reaction using a deproteinisation before the addition of picric acid. The colorimetric intensity of 
the creatinine-picrate complex was measured at 520 nm. Normal creatinine values are between 
0.3 and 3.0 g/l.  
The apparatus used for the urine analysis was an Agilent 6890 gas chromatograph (Agilent 
Technologies AG, Urdorf, Switzerland) equipped with a Gerstel Multipurpose Sampler (Gerstel 
AG, Sursee, Switzerland) operated in headspace mode and with a 2.5 mL tight gas syringe. The 
flame ionization detector (FID) has been used for the determination of the alcohols and the micro 
electron capture detector (-ECD) in the case of the chlorinated compounds. 
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The analyses of the solvents in the end-expired air were performed by using a specially designed 
sampling valve (Droz et al., 1986; Devanthéry et al., 2002), linked to a carbon dioxide detector 
and using a Perkin Elmer GC connected to a Hewlett Packard 3395 integrator. 
 
2.6. Identification of genotypes 
The most studied genetic variants CYP2E1*5B and CYP2E1*6 (Prieto-Castelló et al., 2010) 
were explored. Genotypes of the 25 participants have been identified by using PCR-based RFLP 
methods, as described by Prieto-Castelló et al. (2010). DNA extracted from blood was amplified 
with specific primers (QIAamp DNA Kit, Qiagen). 
The primers used for CYP2E1*5B are described by Cai et al. (2005) and digestion occured 
during 3 hours at 37 °C with Pst I. Non-digested 553 bp fragments represented c1/c1 wild-type 
allele, fragments of 435 + 118 bp represented the c2/c2 genotype and fragments of 553 + 435 + 
118 bp represented the c1/c2 genotype.  
The primers used for CYP2E1*6 are described by Prieto-Castelló et al. (2010) and digestion was 
carried out during 3 hours at 37 °C with Dra I. Non-digested 373 bp fragments represented 
homozygous AA, fragments of 249 + 124 bp represented homozygous wild-type TT and 
fragments of 373 + 249 + 123 bp represented heterozygous TA. 
 
2.7. Symptom questionnaire 
No side effects are expected under these exposure conditions. However, irritation and central 
nervous system effects typical of some solvent exposures cannot be excluded. These possible 
symptoms were self-reported by the volunteers by filling a standard symptom questionnaire at 
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different exposure times. The questionnaire has been taken from a Swedish study (Ernstgård et 
al., 2002), where the ratings were performed using a 0-100 mm visual analogue scale, graded 
from “not at all” (corresponding to 0 mm) through “hardly at all” (6 mm), “somewhat” (26 mm), 
“rather” (48 mm), “quite” (71 mm), “very” (90 mm) to “almost unbearable” (100 mm). The 
symptoms asked for were: discomfort in the eyes, in the nose or in the throat or airways, 
breathing difficulty, solvent smell, headache, fatigue, nausea, dizziness and feeling of 
intoxication. 
 
2.8. Statistical analysis 
The data were first analysed for normality using the Shapiro-Wilk test. Most observations were 
log normally distributed. Besides several studies in volunteers and with toxicokinetic models 
showed that biological results follow approximate lognormal distributions (Droz, 1992). 
Statistical calculations were therefore performed after logarithmic transformation of the 
dependent variables. 
Statistical comparisons between mean values obtained at the end of exposure were made by using 
the Student’s two-sided t-test. The F-test was used to compare variances between groups. 
Univariate analysis of covariance (ANCOVA) was also performed in order to identify potential 
confounders (body mass index, body fat, genotype). Correlations between mean urinary 
concentrations and potential confounders were evaluated by using the Pearson correlation test. 
The significance level was set at α=0.05 and statistical analyses were performed using the 
software package STATA Version 10.  
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Ratings obtained from the symptom questionnaires were not normally distributed. Therefore, the 
Mann-Whitney U test was used to test for differences in symptom ratings between men and 
women.  
 
3. Results 
 
3.1. Human volunteers 
Among all volunteers, only one woman with hormonal contraceptive declined to participate to 
her last exposure session, which concerned 111TCE. The characteristics of each group of human 
volunteers are shown in Table 2. There were no statistically significant differences in age and 
body mass index between the different groups. Body weight and body height were higher for men 
while body fat was higher in women (men vs women with hormonal contraceptive: p = 0.02, p < 
0.001 and p = 0.001, respectively ; men vs women without hormonal contraceptive: p = 0.01, p < 
0.001 and p < 0.001, respectively).  When comparing women with hormonal contraceptive to 
those without, the only statistically significant difference was for body fat (p = 0.008). 
 
Table 2. Characteristics of each volunteer group. Arithmetic mean values ( SD: standard deviation) are indicated; n 
= number of volunteers. 
 Men Women Women with Women without 
 (n=10) (n=15) hormonal contraceptive (n=10) hormonal contraceptive (n=5) 
     
Age (years) 22.4 ± 2.2 23.2 ± 2.9 22.6 ± 2.1 24.4 ± 4.2 
Body weight (kg) 70.7 ± 10.3 61.9 ± 8.7 60.1 ± 7.2 65.6 ± 11.2 
Body height (cm) 177.5 ± 3.2 165.8 ± 3.7 167 ± 3.8 163.4 ± 2.3 
Body Mass Index (-) 22.3 ± 2.6 22.5 ± 3.2 21.6 ± 2.6 24.5 ± 3.7 
Body fat (% of body weight) 11.3 ± 5.2 22.1 ± 6.9 19.8 ± 4.6 26.6 ± 8.9 
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3.2. Air monitoring 
The air concentrations of the selected solvents in the exposure chamber remained very stable over 
time. Slight variations in solvent air concentrations were possible when volunteers went out of 
the chamber for urine sampling. But these variations had little impact on the mean air 
concentrations as the chamber door stayed open for very short moments. All methods of air 
monitoring agreed within 5 %. Air sampling using the tubes containing activated charcoal as 
adsorbent gave following solvents level: 99.15 ( 5.29) ppm for MEK, 53.22 ( 3.04) ppm for 
1M2P and 102.55 ( 3.19) ppm for 111TCE, which corresponded to the intended ones. 
 
3.3. Biological monitoring 
Figures 1-4 show the mean urinary concentrations of the different biomarkers of exposure over 
time for the three groups of human volunteers. Toxicokinetic profiles were similar among all 
groups of volunteers, with differences in the maximal concentration reached. Urinary levels of 
biomarkers of exposure measured among women with hormonal contraceptive were in general 
close to the ones measured among men. Moreover urinary levels were higher in women without 
hormonal contraceptive when biomarkers of exposure corresponded to the unchanged substances 
and the opposite was observed when biological indicators of exposure corresponded to the 
metabolites.  
During exposure, urine was collected every 2 hours. In general, mean values were calculated 
from concentrations obtained for each human volunteer but as urine samples have been collected 
ad lib after exposure, a reduced number of volunteers contributed to the mean urinary levels at  8, 
10, 12 and 14 hours from the beginning of the exposure (for details see captions of Figures 1-4). 
For urinary MEK and urinary 1M2P, adjustment to one g of creatinine was not necessary due to 
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their passive process of elimination in the kidney. In this case compounds secretions vary with 
urine flow rate and creatinine adjustment would not correct for urine dilution. Rather, in the case 
of urinary TCE and urinary TCA, corrections by creatinine gave less variability in the 
toxicokinetic profiles, showing that compensation to urine dilution was necessary.  
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Figure 1 : Urinary MEK concentration as function of time after 6 hours of exposure to 99.15 ( 5.29) ppm MEK. 
Arithmetic mean values ( SD: standard deviation) are indicated; n = number of volunteers. 
Mean urinary levels at 8, 10, 12 and 14 hours from the beginning of the exposure with:  
n = 4, 6, 3 and 6 for women with hormonal contraceptive, 
n = 4, 2, 1 and 4 for women without hormonal contraceptive, 
n = 5, 6, 5 and 6 for men.  
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Figure 2 : Urinary free 1M2P (a) and urinary total 1M2P (b) concentrations as function of time after 6 hours of 
exposure to 53.22 ( 3.04) ppm of 1M2P. Arithmetic mean values ( SD: standard deviation) are indicated; n = 
number of volunteers.  
Mean urinary levels at 8, 10, 12 and 14 hours from the beginning of the exposure with:  
n = 4, 8, 5 and 3 for women with hormonal contraceptive, 
n = 3, 4, 1 and 2 for women without hormonal contraceptive, 
n = 6, 4, 7 and 5 for men. 
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Figure 3 : Urinary TCE concentration as function of time after 6 hours of exposure to 102.55 ( 3.19) ppm of 
111TCE. Arithmetic mean values ( SD: standard deviation) are indicated; n = number of volunteers. 
Mean urinary levels at 8, 10, 12 and 14 hours from the beginning of the exposure with:  
n = 5, 3, 5 and 6 for women with hormonal contraceptive, 
n = 2, 4, 2 and 4 for women without hormonal contraceptive, 
n = 4, 5, 7 and 3 for men. 
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Figure 4 : Urinary TCA concentration as function of time after 6 hours of exposure to 102.55 ( 3.19) ppm of 
111TCE. Arithmetic mean values ( SD: standard deviation) are indicated; n = number of volunteers. 
Mean urinary levels at 8, 10, 12 and 14 hours from the beginning of the exposure with:  
n = 5, 3, 5 and 6 for women with hormonal contraceptive, 
n = 2, 4, 2 and 4 for women without hormonal contraceptive, 
n = 4, 5, 7 and 3 for men. 
 
End-exposure levels for the different urinary biomarkers of exposure, expressed as mean values 
( SD), are summarized in Table 3. Student’s tow-tailed t-tests showed statistically significant 
differences between women with and without hormonal contraceptive for urinary MEK, urinary 
free 1M2P and urinary TCE. For the latter one, statistically significant differences were also 
observed between men and women without hormonal contraceptive. Differences in urinary TCA 
levels were statistically significant between men and women with hormonal contraceptive. From 
the levels of free (aglycone) and total urinary 1M2P, we can deduce that urinary 1M2P is present 
up to 60 % in the conjugated form. 
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111TCE blood concentrations were determined and showed high interindividual variability for all 
the groups. Before exposure, values obtained for men, women with and without hormonal 
contraceptive, respectively were 0.60 (± 0.44), 1.00 (± 0.75) and 0.58 (± 0.33) g/l, end-exposure 
levels were 362.97 (± 91.05), 306.53 (± 152.27) and 371.13 (± 240.64) g/l and measured values 
at the following morning were 16.03 (± 7.71), 10.77 (± 4.46) and 17.86 (± 10.19) g/l. 
Measurements in exhaled air showed that for MEK and 1M2P, mean end-exposure levels were 
very low (about 2 to 3 % of the exposure concentration) with no statistically significant 
differences between the different groups. 
In the case of exhaled 111TCE, mean end-exposure levels corresponded to 27.31 (± 11.09), 28.28 
(± 10.36) and 27.47 (± 6.93) ppm for men, women with and without hormonal contraceptive, 
respectively. The following day, values dropped to 1.98 (± 3.11), 0.69 (± 0.27) and 0.88 (± 0.25) 
ppm. 
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Table 3. Summary of the different biomarkers of exposure values obtained at the end of exposure. Arithmetic mean 
values ( SD: standard deviation) are indicated; n = number of volunteers. 
Biological indicator  Women with Women without  
 Men hormonal hormonal  
 (n=10) contraceptive (n=10) contraceptive (n=5) p-value 
Methyl ethyl ketone 
    
Urinary MEK at the end of exposure (mg/l) 1.00 ± 0.13 0.97 ± 0.23 1.44 ± 0.76 ns*/ns**/0.09***
     
1-Methoxy-2-propanol     
Free urinary 1M2P at the end of exposure (mg/l) 2.99 ± 0.49 2.61 ± 0.96 3.81 ± 1.68 ns/ns/0.1 
Total urinary 1M2P at the end of exposure (mg/l) 4.36 ± 1.76 4.17 ± 1.58 4.85 ± 0.97 ns/ns/ns 
Mean percentages of conjugated 1M2P (%) 
 
26.62 ± 16.77 31.18 ± 34.16 22.70 ± 22.75 ns/ns/ns 
1,1,1-Trichloroethane     
Urinary TCE at the end of exposure (mg/l) 
Urinary TCE at the end of exposure (mg/g creatinine) 
5.66 ± 2.20 
5.42 ± 2.19 
3.83 ± 1.26 
6.46 ± 1.73 
2.09 ± 1.24 
3.77 ± 1.24 
ns/0.01/0.03 
ns/0.08/0.01 
Urinary TCA at the end of exposure (mg/l) 
Urinary TCA at the end of exposure (mg/g creatinine) 
0.20 ± 0.23 
0.18 ± 0.20 
0.16 ± 0.08 
0.26 ± 0.12 
0.11 ± 0.09 
0.21 ± 0.18 
ns/ns/ns 
0.08/ns/ns 
111TCE in blood at the end of exposure (g/l) 362.97 ± 91.05 306.53 ± 152.27 371.13 ± 240.64 ns/ns/ns 
Exhaled 111TCE at the end of exposure (ppm) 27.31 ± 11.09 28.28 ± 10.36 27.47 ± 6.93 ns/ns/ns 
 
*  Student’s two-tailed t-test between men and women with hormonal contraceptive 
**  Student’s two-tailed t-test between men and women without hormonal contraceptive 
***  Student’s two-tailed t-test between women with and without hormonal contraceptive 
 
with  ns: not significant (p > 0.1) 
 
3.4. Genotypes 
Genotyping results for the CYP2E1*5 allele showed that among the participants, only one person 
presented the heterozygous type variant (c1/c2). Concerning the CYP2E1*6 allele, results 
showed that 21 volunteers (84 %) had the wild type variant (TT) and four (16 %) the 
heterozygous one (TA). Among the carriers of the mutant allele, one belonged to the group of 
men, another to the group of women with hormonal contraceptive and two to the group of women 
without hormonal contraceptive. For the latter, one of both was also the carrier of the 
heterozygous type variant (c1/c2) for genotype CYP2E1*5. 
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In view of the fact that the number of volunteers participating to the study is low, the number of 
persons carrying the mutant alleles of the CYP2E1 genotypes is even lower. Thus it was not 
possible to perform a statistical analysis on the genotype CYP2E1*5. Table 4 summarizes the 
results obtained after performing an ANCOVA analysis on the different biomarkers of exposure 
levels obtained for the studied volunteers groups. 
 
Table 4. Results (F-ratios and p-values obtained from ANCOVA analysis) in order to identify potential confounders 
in evaluating differences, when exposed to organic solvents, between men and women with hormonal contraceptive 
(abbreviated in the table as horm. contr.), between men and women without hormonal contraceptive and between 
women with hormonal contraceptive and those without. Potential confounders considered: Body Mass Index (BMI), 
body fat (BF) and genotype CYP2E1*6. 
 
 
Independent 
variables 
Dependent variables 
 CMEK,urine 
(mg/l) 
Cfree1M2P,urine 
(mg/l) 
Ctotal,1M2P,urine 
(mg/l) 
CTCE,urine 
(mg/ g creatinine) 
CTCA,urine 
(mg/ g creatinine) 
 F-ratio p-value F-ratio p-value F-ratio p-value F-ratio p-value F-ratio p-value 
 Men vs women with hormonal contraception 
sex 4.61 0.05 0.83 0.38 0.99 0.34 0.25 0.62 0.79 0.39 
BMI 1.63 0.22 0.21 0.65 2.94 0.11 0.02 0.88 0.10 0.76 
BF 12.03 0.003* 4.06 0.06** 0.92 0.35 0.11 0.74 0.05 0.83 
CYP2E1*6 6.11 0.03 0.19 0.67 1.82 0.19 0.00 0.98 1.72 0.21 
 
 Men vs women without hormonal contraception 
sex 4.06 0.07 0.75 0.41 0.02 0.88 0.76 0.40 0.02 0.90 
BMI 0.34 0.57 0.18 0.68 0.27 0.61 0.08 0.78 0.17 0.69 
BF 0.24 0.64 0.26 0.62 0.09 0.77 0.05 0.83 0.25 0.63 
CYP2E1*6 1.38 0.27 0.94 0.36 0.29 0.59 0.91 0.36 0.83 0.38 
 
 Women with hormonal contraception vs women without  
horm. contr. 11.89 0.006 16.71 0.002 1.23 0.29 8.88 0.01 2.51 0.15 
BMI 0.31 0.59 0.18 0.68 0.77 0.40 0.32 0.59 0.02 0.89 
BF 1.25 0.29 15.11 0.003*** 0.01 0.93 0.02 0.89 0.00 0.97 
CYP2E1*6 0.41 0.54 6.99 0.02 1.81 0.21 0.01 0.93 0.61 0.45 
 
* Pearson correlation matrix (correlation coefficient: -0.55, p = 0.01) 
** Pearson correlation matrix (correlation coefficient: -0.58, p = 0.01) 
***  Pearson correlation matrix (correlation coefficient: -0.35, p = 0.19) 
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The statistical analysis showed that body fat and genotype could be potential confounders when 
differences in urinary levels of biomarkers of exposure are observed between men and women.  
When comparing men with women using hormonal contraceptives, body fat clearly influenced 
urinary concentrations for MEK and 1M2P. The Pearson correlation matrix confirmed a negative 
association in both cases. The genotype CYP2E1*6 when considered as covariate also showed a 
statistically significant p-value but the fact that only two persons were carrier of the mutant allele 
among the compared groups makes it difficult to deduce any affirmation. Urinary MEK 
concentrations for both volunteers in question were 0.93 mg/l and 0.75 mg/l, respectively. For the 
other two persons who belonged to the group of women without hormonal contraception, the 
measured urinary MEK concentrations were 0.73 mg/l and 1.35 mg/l, respectively, the latter one 
being the volunteer carrying also the heterozygous type variant (c1/c2) for genotype CYP2E1*5. 
Thus, when comparing these values with the mean urinary MEK levels obtained for each group 
of participants (see Table 3), there may be a tendency to have a higher CYP2E1 activity when the 
participant is carrier of the mutant allele of the genotype CYP2E1*6 only. 
When comparing men with women without hormonal contraception, results showed no 
statistically significant p-value.  
Finally, when comparing women using hormonal contraceptives with those who are not under 
hormonal contraception, results showed an effect due to the use of exogenous hormones for the 
three studied solvents. Moreover, in the case of 1M2P, body fat and genotype seem to be 
potential confounders. But the Pearson correlation matrix did not confirm an association between 
body fat and our dependent variable. For the CYP2E1*6 genotype, it is once again difficult to 
deduce something relevant due to the low number of participants carrying the mutant allele. The 
woman using hormonal contraceptives had a value of 3.05 mg/l of free 1M2P in urine. For the 
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two women without hormonal contraception, the urinary free 1M2P concentrations were 2.86 
mg/l and 4.07 mg/l, respectively, the latter one being the volunteer carrying also the heterozygous 
type variant (c1/c2) for genotype CYP2E1*5. The only man carrying the genetic variant of 
CYP2E1*5 had a value of 3.11 mg/l of free 1M2P in urine. Here, when comparing these values 
with the mean urinary free 1M2P levels obtained for each group of participants (see Table 3), any 
tendency cannot be deduced. 
 
3.5. Symptom questionnaire 
The self-reported symptom questionnaire was distributed every 2 hours during exposure. The 
medical responsible saw the volunteers for possible symptoms before exposure, after exposure 
and in the morning of the following day.  
Highest ratings were obtained for methyl ethyl ketone followed by 1-methoxy-2-propanol and the 
lowest one for 1,1,1-trichloroethane. Considering only the irritation symptoms (eyes, nose, 
throat), we can observe statistically significant differences between men and women, the latter 
ones giving higher ratings. The Mann-Whitney U test gave p values lower than 0.1 for discomfort 
in the eyes for exposure to MEK (after two and four hours) and to 1M2P (after two hours), for 
discomfort in the nose after six hours of exposure to 1M2P and to 111TCE, and for discomfort in 
the throat after four hours of exposure to 1M2P. The solvent smell was perceived by most of the 
volunteers at the beginning of the exposure. It seems that men got used more to the solvent odour 
than women who gave still a rather high score at the end of exposure (p = 0.01 after four hours of 
exposure to MEK and p = 0.06 after six hours of exposure to 1M2P). There were also higher 
ratings among women concerning headache, after four and six hours of exposure to MEK (p = 
0.04 and p = 0.06, respectively). Women were more tired than men after six hours of exposure to 
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MEK (p = 0.06) and the opposite was observed after four hours of exposure to 1M2P (p = 0.03). 
Finally, women had a higher feeling of intoxication than men at the end of exposure of MEK and 
1M2P (p = 0.09 in both cases). 
 
4. Discussion 
Our study suggests that not only physiological differences between men and women but also 
differences due to sex hormones levels can have an impact on urinary concentrations of several 
indicators of exposure. The measured values are of the same order of magnitude as data found in 
literature (Caperos et al., 1982; Devanthéry et al., 2002; Imbriani and Ghittori, 2004). When 
comparing to the biological exposure indices, we can estimate, by taking into account the 
exposure conditions, that we generally do not exceed them. In the case of TCA, values are very 
low, which is due to its long half-life time. Accumulation is possible during the week and thus, it 
is not an appropriate biomarker for reflecting a daily exposure.   
Univariate analysis of variance, performed after logarithmic transformation of the independent 
variables and by adjusting for potential confounders (body mass index, body fat, genotype), 
showed the following main observations: 
o a negative correlation between body fat and urinary MEK as well as urinary free 1M2P 
concentrations when comparing men with women using hormonal contraceptives; 
o a difference due to the genotype CYP2E1*6, when exposed to methyl ethyl ketone, with a 
tendency to increase CYP2E1 activity when volunteers are carrier of the mutant allele; 
o an effect among women due to the use of hormonal contraceptive on the urinary levels of 
several biomarkers of exposure, with an increase of more than 50 % in metabolites 
concentrations and a decrease of up to 50 % in unchanged substances concentrations, 
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suggesting an increase in their metabolism rate. 
Body composition can influence the toxicokinetic behaviour of a substance (Sato et al., 1991). 
Men have generally higher lean body mass and women have higher body fat. The distribution of 
lipophilic compounds can especially be modified, as higher body fat increases the distribution 
volume for a lipophilic substance. Thus a decrease in the excretion rate of both the substance 
itself and its metabolites can be a consequence. Final urinary concentrations should also be lower 
in women than in men. But when looking at the measured values of the different biological 
indicators of exposure, we can see that mean values obtained for women can be higher than those 
obtained for men as it is the case when the unchanged substance is determined. Moreover, among 
women, there is an obvious difference between those under hormonal contraceptive and those 
not. Thus parameters other than the physiological ones could explain the differences observed 
between the volunteer groups. 
According to several authors (Tanaka, 1998; Clewell et al, 2002; Parkinson et al., 2004), 
enzymatic activities of CYP1A2, CYP3A4, CYP2D6, and CYP2E1 are usually higher in males 
than in females, a tendency reflected by our results but which can not be confirmed as the 
volunteers’ phenotypes have not been measured.  
Concerning genetic polymorphism in CYP2E1, Prieto-Castello et al. (2010) observed a reduced 
activity of CYP2E1 in the presence of CYP2E1*5 and CYP2E1*6 variant alleles. Our results 
showed the opposite, which could be explained by the very low number of carriers of the variant 
allele or by an eventual high interindividual variability in CYP2E1 enzyme activity (Bebia et al., 
2004).  
A recent publication about gender differences in drug toxicity (Nicolson et al., 2010) supports the 
idea that hormonal interaction could play a key role. Actually, the effect due to hormonal 
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contraceptive was the most outstanding from the ANOVA analysis albeit the number of women 
for this comparison was low. 
In a recent review of Kennedy (2008) about hormonal regulation of hepatic drug-metabolizing 
enzyme activity, it is has been shown that estrogens decrease hepatic microsomal activity and 
drug clearance in rodents. Evidence from clinical studies (Scandlyn et al., 2008) suggests that the 
CYP2E1 enzyme activity is lower in females than in men. The author states that CYP2E1 appears 
to be estrogen-regulated and that a reduced activity has been described during periods when 
estrogen levels remain elevated (pregnancy) or during changes in hormone levels (puberty, 
exogenous hormone administration). 
In fact, combined oral contraceptives increase the estrogen and progesterone levels while 
decreasing the gonadotropins level (Kennedy, 2008). The increase in estrogen has as 
consequence an increase in the sex hormone-binding globulin (SHBG) level (Panzer et al., 2006), 
which has a high affinity and a low capacity for testosterone and estradiol (Pugeat et al., 2009). 
Albumin regulates the access of steroids to their receptors (Baker, 2002). The increase in SHGB 
level can enable steroids, bound with low affinity to albumin, to bind to SHGB. These variations 
in protein binding levels will have an impact on the balance between bound and unbound 
substances, and thus on hormonal activity. Xenoestrogens, as ethinylestradiol in hormonal 
contraceptive, bind to SHGB with low affinity, and are generally bounded to albumin. 
One possible consequence of this imbalance in protein levels due to hormonal contraceptives 
could be a lower free estradiol level. Actually, free estradiol level is lower in women under 
hormonal contraceptive than women without hormonal contraceptive (Bjornerem et al., 2004). 
Thus, when combining Kennedy’s hypothesis with our observations, we conclude that the use of 
hormonal contraceptives like the combined contraceptive pill may increase CYP2E1 activity. 
 109 
 
Moreover, it seems to be more correct to say that the free estradiol level influences CYP2E1 
activity instead of the estrogen level. 
When comparing results obtained for free and total urinary 1M2P, we observed that an important 
part of the 1M2P is present in its conjugated form. Thus it is relevant to determine the total 
urinary 1M2P concentration when assessing human exposure to 1M2P. Besides, women on 
hormonal contraceptives appeared to excrete a higher fraction as conjugate than those not taking 
hormonal contraception. This may indicate that sex hormones levels also influence the enzyme 
activity of phase II reactions (Miners et al., 1983; Kennedy, 2008). 
Creatinine correction is usually used in spot urine analysis and accounts for differences in urine 
flow and concentration. However, creatinine excretion depends on the muscle mass, which is 
higher in men than in women. In fact, when urinary TCE and TCA concentrations were adjusted 
to creatinine, sex differences became more pronounced. 
Regarding the average symptom ratings obtained for each group of volunteers, we noticed that 
women rated irritating symptoms generally higher than men. It is interesting to see that even at 
half the threshold limit value, volunteers perceived irritating symptoms, solvent smell and 
headache. Fatigue belonged also to the high rated symptoms, but as it has been shown in a 
previous study (Ernstgård et al., 2002), there was in general no significant difference between 
volunteers exposed to clean air and those exposed to a solvent, making this symptom unspecific 
for solvent exposure.  
As volunteers of this study belonged to a narrow range of age, the biological variability due to 
age was limited. However, due to the low number of participants, as it is often the case for 
studies with human volunteers, we observed an important interindividual variability among the 
participants groups, especially among women who did not take hormonal contraceptive. Despite 
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a severe volunteer profile, some participants groups were less homogenous than others. Several 
factors could thus contribute to the observed variability within a group, as for example body fat 
or the CYP2E1 activity itself (Bolt et al., 2003). But regarding women without hormonal 
contraceptives, this variability could also be related to the hormonal variation during the 
menstrual cycle, as they were exposed at any point of their cycle. The hormonal fluctuations are 
characterized by high estrogen levels during ovulation and high progesterone levels during the 
luteal phase. Nevertheless, it was possible to underline some statistically significant differences 
between the studied human volunteer groups. 
In conclusion, our results suggest that there exist differences between men and women when 
exposed to organic solvents which could be explained not only by physiological differences but 
also by differences in CYP2E1 enzyme activity. For same exposure conditions, biological 
exposure indices can differ between men and women, which can lead to a misinterpretation of 
biomonitoring results. This aspect should have its place in the approaches for setting limits of 
occupational exposure as the existing recommended biological limits for chemical substances are 
most based on a direct correlation with the corresponding threshold limit values.  
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ABSTRACT 
Toxicokinetic modeling is a useful tool to describe or predict the behavior of a chemical agent 
in the human or animal organism. A general model based on four compartments was developed 
in a previous study in order to quantify the effect of human variability on a wide range of 
biological exposure indices.     
The aim of this study was to adapt this existing general toxicokinetic model to three organic 
solvents, which were methyl ethyl ketone, 1-methoxy-2-propanol and 1,1,1,-trichloroethane, and 
to take into account sex differences. We assessed in a previous human volunteer study the impact 
of sex on different biomarkers of exposure corresponding to the three organic solvents mentioned 
above. Results from that study suggested that not only physiological differences between men 
and women but also differences due to sex hormones levels could influence the toxicokinetics of 
the solvents. These experimental data were used to validate the toxicokinetic models developed 
in this study. 
Our results showed that it was possible to use an existing general toxicokinetic model for other 
compounds. In fact, most of the simulation results showed good agreement with the experimental 
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data obtained for the studied solvents. Results pointed out that for same exposure conditions, men 
and women can show important differences in urinary levels of biological indicators of exposure. 
Moreover, when running the models by simulating industrial working conditions, these 
differences could even be more pronounced.  
In conclusion, a general and simple toxicokinetic model, adapted for three well known organic 
solvents, allowed us to show that metabolic parameters can have an important impact on the 
urinary levels of the corresponding biomarkers. These observations give evidence of an 
interindividual variablity, an aspect that should have its place in the approaches for setting limits 
of occupational exposure. 
 
Key words: Toxicokinetic modeling - Human biomonitoring - Sex differences – Organic 
solvents 
 
 
INTRODUCTION 
Toxicokinetic (TK) modeling is a useful tool to describe or predict the behavior of a chemical 
agent in the human or animal organism. Interest in it arose from the need to relate internal 
concentrations of active compounds with the external exposure conditions.(1) Data-based 
pharmacokinetic models were first developed in the 1920’s and several disciplines like inhalation 
anesthesia, chemical engineering, toxicology or computer sciences, contributed to their 
maturation throughout the last decades.(2) Fiserova-Bergerova for example contributed 
intensively to the development of toxicokinetic models for inhaled organic solvents in humans.(3-
5) 
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Depending on the substance, the complexity of the kinetics and the literature data available, 
two types of models can be used.(6) Classical toxicokinetic (TK) models, represented by 
compartments within which the chemical is assumed to be homogeneously distributed, are 
suitable when limited toxicological data is available. They are limited from a structural point of 
view but can be used to make generalizations. Physiologically-based toxicokinetic (PBTK) 
models, which rely on the anatomical and physiological structure of the body, are preferred when 
the purpose is to know the substance’s concentration in different tissues or organs. They are more 
informative and usually allow for a better extrapolation processes. 
Several authors investigated the quantification of biological variability through TK/PBTK 
modeling. Droz et al.(7), for example, developed a PBTK model for differing workers under 
variable industrial environments while Pierrehumbert et al.(8) tried to develop a general 
compartmental based TK model. The variability extent index and the main parameters affecting 
biological indicators were investigated by Truchon et al.(9) while the impact of environmental 
variability was quantified by Berthet et al.(10).  
The influence of sex on toxicokinetics may involve female-male differences in physical 
constitution (body water space, muscle mass, body fat, and blood flow), physiology (menopause 
and menstruation cycle), hormones (contraceptive pill) as well as metabolizing enzymes (Löf et 
al., 1998).(11) 
Clewell et al.(12) have described the contribution of sex (and age) to biological variability by 
developing a PBPK model to determine the tissue concentration as a function of time of some 
xenobiotics. This work represents an initial attempt to provide a predictive toxicokinetic 
framework and should for now be considered to represent reasonable expectations rather than a 
quantitative tool.  
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It is presently still very difficult to assess the variability associated with biological monitoring 
results. Although we can establish a list of contributing factors, as shown in a framework for sex 
differences by Gochfeld(13), their relative importance is unknown for different chemicals of 
occupational interest. It is therefore presently impossible to use such information to interpret 
biological variability and make safer quantitative decisions when using biological monitoring of 
exposure. 
The aim of this study was to adapt an existing general toxicokinetic model to three organic 
solvents, which were methyl ethyl ketone (MEK), 1-methoxy-2-propanol (1M2P) and 1,1,1,-
trichloroethane (111TCE), and to take into account sex differences. The influence of sex on 
different biological indicators had been evaluated in a human volunteer study(14) by exposing 
volunteers to the three organic solvents mentioned above. Experimental data from that study was 
used to validate the present models. 
 
MATERIAL AND METHODS 
Model description 
Pierrehumbert et al.(8) have developed a general compartmental model in order to quantify the 
effect of human variability on a wide range of biological exposure indices (BEIs). By applying it 
to four chemicals (toluene, phenol, lead and mercury), they showed its potential to be used for 
further substances. We actually underline this potential of the model by adapting it to three other 
compounds which are MEK, 1M2P and 111TCE.  
The general compartmentally based toxicokinetic model developed by Pierrehumbert et al.(8) 
consists of four compartments and takes into account only absorption by inhalation, as BEIs 
establishment does not consider oral or skin absorption. In fact most of BEIs are based on a direct 
correlation with the threshold limit values (TLVs) which indicate the potential exposure by 
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inhalation of a worker. The air absorption rate is equal to the product of the exposure 
concentration and the alveolar ventilation scaled to body weight, the whole multiplied by the 
pulmonary retention if applied. The chemical is distributed between the central compartment and 
the peripheral one, or storage compartment. These compartments can be illustrated by different 
tissues, depending on the chemical. The distribution can be either flow or diffusion limited and 
includes the permeability and affinity of the tissue for the chemical. For transfer between central 
and peripheral compartments, rates are expressed as a function of blood flow, affinity and 
permeability. The metabolism, described with Michaelis–Menten kinetics, can give one or more 
metabolites, and can occur by serial or parallel metabolism. Elimination is represented by 
excretion in expired air, feces and urine, or by metabolism. The air excretion rate is equal to the 
product of the concentration in the central compartment and the alveolar ventilation scaled to 
body weight, the whole divided by the blood/air partition coefficient. For excretion, estimated 
rates are based either on the half-life of the chemical/metabolite, or on its clearance (e.g. bile flow 
for feces, urine flow for urine, alveolar ventilation for expired air) and volume of distribution. 
More detail about the mathematical equations describing the general model can be found in 
Pierrehumbert et al.(8).  
This general model was adapted to MEK, 1M2P and 111TCE using toxicokinetic data 
available in the literature.(15-21) The simulation software used for the development of the TK 
models was Berkeley Madonna (version 8.0.1.), developed by Robert Macey and George Oster of 
the University of California at Berkeley (USA). 
 
Human volunteer study 
Experimental data were taken from a previous human volunteer study.(14) Three chemicals 
have been selected for their relatively low toxicity as well as their metabolic and physiological 
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properties: MEK, watersoluble and highly metabolized, 1M2P, amphiphile and highly 
metabolized, and 111TCE, liposoluble and poorly metabolized.  
Controlled human exposures were carried out in a 12 m3 exposure chamber for each solvent 
separately, during six hours and at half of the threshold limit value (TLV). The human volunteers 
groups were composed of ten young men and fifteen young women. The latter were separated 
into two sub-groups by taking into account the use or not of hormonal contraceptive. The 
characteristics of each volunteer group are summarized in Table I (Tomicic et al.(14)). 
 
TABLE I. Characteristics of each volunteer group. Arithmetic mean values ( SD: standard deviation) are indicated; 
n = number of volunteers. 
 
 Men Women Women with Women without 
 (n=10) (n=15) hormonal contraceptive 
(n=10) 
hormonal contraceptive 
(n=5) 
     
Age (years) 22.4 ± 2.2 23.2 ± 2.9 22.6 ± 2.1 24.4 ± 4.2 
Body weight (kg) 70.7 ± 10.3 61.9 ± 8.7 60.1 ± 7.2 65.6 ± 11.2 
Body height (cm) 177.5 ± 3.2 165.8 ± 3.7 167 ± 3.8 163.4 ± 2.3 
Body Mass Index (-) 22.3 ± 2.6 22.5 ± 3.2 21.6 ± 2.6 24.5 ± 3.7 
Body fat (% of body weight) 11.3 ± 5.2 22.1 ± 6.9 19.8 ± 4.6 26.6 ± 8.9 
 
 
Following biological indicators of exposure were determined: urinary MEK, urinary 1M2P 
(conjugated and total), 111TCE in blood and in expired air, metabolites of 111TCE 
(trichloroethanol (TCE) and trichloroacetic acid (TCA)) in urine. The corresponding BEIs are 
summarized in Table II (Tomicic et al.(14)). 
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TABLE II. Summary of the selected organic solvents and their corresponding urinary biomarkers of exposure, with 
the existing occupational exposure limit values and biological exposure indices for different countries (USA, 
Germany, Switzerland) 
 
  
Biological determinant TLV*/MAK**/VME*** BEI*/BAT**/VBT*** 
  (ppm) in urine (mg/l) 
Methyl ethyl ketone (MEK) 200/200/200 2/5/5 a 
      
1-Methoxy-2-propanol (1M2P) 100/100/100 -/15/20 a 
      
1,1,1-Trichloroethane (111TCE) 350/200/200  - 
Trichloroethanol (TCE)   30/-/- a,b 
Trichloroacetic acid (TCA)   10/-/- b 
 
* The American Conference of Industrial Hygienists (ACGIH) sets threshold limit values (TLV) and biological 
exposure indices (BEI). 
 
**  The German Research Foundation (Deutsche Forschungsgemeinschaft - DFG) sets “Maximale Arbeitsplatz-
Konzentrationen”  (MAK) and “Biologische Arbeitsstoff-Toleranzen” (BAT). 
 
*** The Swiss National Accident Insurance Fund (Schweizerische Unfallversicherungsanstalt - Caisse nationale 
suisse d'assurance en cas d'accidents - Istituto nazionale svizzero di assicurazione contro gli infortuni - SUVA) 
sets “valeurs (limites) moyennes d’exposition” (VME) and “valeurs biologiques tolérables” (VBT). 
 
a ES: end of shift  b EW: end of week  c PS: prior to shift 
 
 
Model parameters 
The only measured parameters in the frame of the human volunteer study were body weight, 
body height and body fat. Thus their values in the models corresponded to the arithmetic means 
obtained for each quite homogenous group of human volunteers who have participated to this 
study. Values for general physiological parameters like alveolar ventilation, cardiac output or 
organ blood flows corresponded to the values of a reference man. These were scaled in function 
of body weight. Otherwise, values were taken from literature, like partition coefficients or 
metabolic parameters.  
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Simulation conditions 
The three toxicokinetic models were first calibrated with the experimental data obtained 
during the previous human volunteer study(14).  
In a second step, simulations were performed to mimic an occupational exposure at the TLV 
(8 h per day, 5 days per week, physical activity of 50 W for 12 h per day and at rest for the 
resting 12 hours).  
Lastly, concentrations of the studied substances can be predicted in other biological matrices 
or tissues, as for example in blood (corresponding to the central compartment of the model) or in 
fat (corresponding to the peripheral compartment of the model).   
 
RESULTS 
Toxicokinetic models for MEK, 1M2P and 111TCE 
In most occupational exposure settings, the primary intake route for the three studied solvents 
is inhalation. The different compartmental TK models for the studied solvents, all metabolized 
via the cytochrome P450 mixed-function oxidase system, are illustrated on Figure 1. 
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(a)        (b)                (c) 
 
 
 
 
 
 
 
 
 
 
 
 
          
FIGURE 1. Illustration of the different compartmental based TK models for (a) MEK, (b) 1M2P and (c) 111TCE, 
with the black arrows indicating the biological determinants considered in this study, and with following flow rates 
air absorption (AA), air excretion (AE), urinary excretion (UE), metabolism (Met) and conjugation (Conj) expressed 
as [mg/h]. 
 
MEK is metabolized to 2,3-butanediol, 2-butanol and 3-hydroxy-2-butanone (major 
metabolite), all excreted in urine. A low fraction of unchanged solvent is excreted in the exhaled 
air. The urinary concentration of MEK at the end of the shift has been recommended as the most 
appropriate biological exposure indicator. MEK is nearly equally distributed between water and 
fat containing tissues.(22) Thus the model is composed by a central compartment representing the 
total body water (TBW) and a peripheral compartment for the fatty tissues. 
1M2P belongs to the family of the propylene glycol ethers (PGE) which exists under the form 
of two isomers, alpha-isomer and beta-isomer. The latter one, considered as an impurity in 
commercial use, is first transformed into 2-alkoxy acetaldehydes by alcohol dehydrogenases, and 
then into alkoxyacetic acids by aldehyde dehydrogenases, a toxic metabolite. Alpha-PGE are 
primarily metabolized to propylene glycol, carbon dioxide and glucuronide as well as sulfate 
conjugates of the parent compound. The urinary 1M2P concentration at the end of the shift is the 
appropriate biomarker. A central compartment equivalent to TBW and a second compartment 
illustrating the conjugation of 1M2P constitute the TK model for 1M2P. 
Met 
UE 
UE 
UE 
Met 
Met 
UE AA 
AE AE AE 
AA AA 
Conj Met 
Central Central Central 
Peripheral Peripheral 
Conjugation Metabolite 
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111TCE is metabolized to TCE and TCA, both excreted in urine. Other minor metabolites 
(carbon dioxide, acetylene) are excreted in the exhaled air. The corresponding biological 
exposure indices are the urinary concentration of both metabolites and the blood concentration of 
the parent compound. The 111TCE concentration in the exhaled air can also be considered as a 
biomarker of exposure. As the exposure scenarios were carried out during one day, urinary TCE 
is the most appropriate biomarker for the model calibration with the experimental data. Thus the 
TK model includes a central compartment equivalent to TBW, a peripheral one constituting the 
fatty tissues because of its high liposolubility, and a third compartment for the considered 
metabolite. 
The general physiological parameters used in the simulations are presented in Table III 
whereas the chemical specific parameters for each TK model are represented in Table IV. 
 
TABLE III. General physiological parameters used for the TK models 
 
Parameters Symbol At rest/50 W 
Body weight [kg] 
Body height  [cm] 
BW 
BH 
Arithmetic mean value for each group of human volunteers 
Arithmetic mean value for each group of human volunteers 
Body fat [kg] 
Lean body mass [kg] 
 
Total body water [kg] 
BF 
LBM 
 
TBW 
Arithmetic mean value for each group of human volunteers 
LBM = BW – BFa 
 
For a man : -12.86 + 0.1757 * BH + 0.3331 * BW a 
  For a woman : -2.097 + 0.1069 * BH + 0.2466 * BWa 
Cardiac output [l/(h*kg0.7)] 
Alveolar ventilation [l/(h*kg0.7)] 
Urinary excretion rate [ml/(h*kg0.82)] 
Creatinine excretion rate [mol/(h*kg0.9)] 
Qc 
Valv 
kur 
kcr 
18.0b/30.8b
18.0b/2.1951*Qcb 
1.848c 
12.06c 
 
a Fiserova-Bergerova(23) 
b Thomas et al.(24) 
c Laparé et al.(25) 
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TABLE IV. Chemical specific parameters used for the TK models 
 
Parameters Symbol At rest/50 W 
MEK 
Threshold limit value [mg/m3] 
Molecular weight [g/mol] 
Exposure concentration [mg/m3] 
 
TLV 
MW 
Cexp 
 
590 
72 
282.9 
Pulmonary retention [-] Rpulm 0.558a 
Volume of the central compartment expressed as a fraction of BW [-] 
Volume of the peripheral compartment expressed as a fraction of BW [-] 
Fraction of cardiac output in the peripheral compartment [-] 
Fraction of cardiac output in metabolism [-] 
Blood/air partition coefficient [-] 
Central/blood partition coefficient [-] 
Peripheral/central partition coefficient [-] 
Metabolism 
Michaelis-Menten maximum rate** [mg/(h*kg0.75)]  
Michaelis-Menten constant* [mg/l] 
 
1M2P 
Threshold limit value [mg/m3] 
Molecular weight [g/mol] 
Exposure concentration [mg/m3] 
Pulmonary retention [-] 
Volume of the central compartment expressed as a fraction of BW [-] 
Fraction of cardiac output in metabolism [-] 
Blood/air partition coefficient [-] 
Central/blood partition coefficient [-] 
Metabolism 
Michaelis-Menten maximum rate*,** [mg/(h*kg0.75)]  
Michaelis-Menten constant* [mg/l] 
Conjugation 
Michaelis-Menten maximum rate*** [mg/(h*kg0.75)]  
Michaelis-Menten constant* [mg/l] 
Urinary excretion rate for conjugated 1M2P [h-1] 
 
111TCE 
Threshold limit value [mg/m3] 
Molecular weight [g/mol] 
Molecular weight of metabolite [g/mol] 
Molecular weight of creatinine [g/mol] 
FVc 
FVp 
BFp 
BF1 
Pblood_air 
Pc_air 
Pp_c 
 
VM1 
KM1 
 
 
TLV 
MW 
Cexp 
Rpulm 
FVc 
BF1 
Pblood_air 
Pc_blood 
 
VM1 
KM1 
 
VM2 
KM2 
kconj 
 
 
TLV 
MW 
MW1 
MWcr 
1*TBW/BW 
1*BF/BW 
0.06b/0.05b 
0.26b/0.16b 
125a 
0.856a 
1.296a 
 
5.44c 
0.63c 
 
 
360 
90.12 
177.1 
0.9d 
1*TBW/BW 
0.26b/0.16b 
12383e 
12280e 
 
22f 
45f 
 
0.2f 
80f 
0.2d 
 
 
1080 
133.40 
149.40 
113.12 
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Exposure concentration [mg/l] 
Pulmonary retention [-] 
Volume of the central compartment expressed as a fraction of BW [-] 
Volume of the peripheral compartment expressed as a fraction of BW [-] 
Volume of the metabolite compartment expressed as a fraction of BW [-] 
Fraction of cardiac output in peripheral compartment [-] 
Fraction of cardiac output in metabolite compartment [-] 
Blood/air partition coefficient [-] 
Central/air partition coefficient [-] 
Peripheral/air partition coefficient [-] 
Metabolite/air partition coefficient [-] 
Metabolism 
Michaelis-Menten maximum rate** [mg/(h*kg0.75)]  
Michaelis-Menten constant [mg/l] 
Metabolic rate TCE  TCA [1/(h*kg-0.3)] 
Excretion 
TCE urinary excretion rate [1/(h*kg-0.3)] 
Cexp 
Rpulm 
FVc 
FVp 
FV1 
BFp 
BF1 
Pblood_air 
Pc_air 
Pp_air 
PM1_air 
 
VM1 
KM1 
kM1_M2 
 
ku1 
545.6 
0.25g 
1*TBW/BW 
1*BF/BW 
0.026h 
0.06b/0.05b 
0.26b/0.16b 
2.53i 
2.53i 
263i 
8.6i 
 
0.42i 
5.75i 
0.069j 
 
 
0.093j 
 
a Liira et al.(22) 
b Thomas et al.(24) 
c Thrall et al.(19) 
d   Devanthéry(26) 
e    Johanson et al.(27) 
f  Corley et al.(20) 
g  Nolan et al.(28) 
h Tardif et al.(29) 
i  Reitz et al.(15) 
j  Caperos et al.(30) 
 
* When fitting toxicokinetic models to our experimental data obtained for men, metabolic parameters have been adapted, 
with  
- KM1 = 1.1 mg/l for the MEK model ; 
- VM1 = 30 mg/(h*kg0.75), KM1 = 30 mg/l and KM2 = 95 mg/l for the 1M2P model. 
** When fitting toxicokinetic models to our experimental data obtained for women without hormonal contraceptive, 
metabolic parameters have been modified, by reducing the Michaelis-Menten maximum rate value by half, with 
- VM1 = 2.7 mg/(h*kg0.75) for the MEK model ; 
- VM1 = 15 mg/(h*kg0.75) and VM2 = 0.1 mg/(h*kg0.75) for the 1M2P model ; 
- VM1 = 0.21 mg/(h*kg0.75) for the 111TCE model. 
*** Based on Miners et al.(31) observations, the Michaelis-Menten maximum rate value for conjugation was reduced by 45 
% for the group of women without hormonal contraceptive, with 
- VM2 = 0.11 mg/(h*kg0.75) for the 1M2P model. 
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Experimental data vs simulated data  
The conclusion of the human volunteer study(14) was that there exist differences between men 
and women when exposed to organic solvents which could be explained not only by 
physiological differences but also by differences in CYP2E1 enzyme activity. An analysis of 
variance mainly showed an effect on the urinary levels of several biomarkers among women due 
to the use of hormonal contraceptive,  with an increase of about 50 % in the metabolism rate. 
In a first step, the TK models of the three studied solvents were calibrated with  the 
experimental data obtained for the male human volunteers, showing generally good agreement 
between both. Metabolic parameters for MEK and 1M2P have been fitted to our experimental 
data, with focusing on a good agreement for the urinary levels measured during the exposure to 
the solvent, that means for t=2, t=4 and t=6 hours. In literature, these values were actually fitted 
to data(19,20), for MEK and 1M2P but not for 111TCE.   
Thus, in the case of MEK metabolism, the Michaelis-Menten constant value taken from 
literature was adapted to our experimental data, with KM1 = 1.1 mg/l. In the case of 1M2P 
metabolism, the Michaelis-Menten maximum rate and constant values taken from literature were 
adapted to our experimental, with VM1 = 30 mg/(h*kg0.75), KM1 = 30 mg/l and KM2 = 95 mg/l. 
When changing physiological parameters with the values for the female human volunteers 
groups, biological indicators levels were slightly influenced but still in good agreement with the 
experimental data. 
The main observation was that the agreement between experimental and simulated values was 
merest for the group of women without hormonal contraceptive. On basis of the emitted 
hypothesis in the previous human volunteer study(14), suggesting that there was a mean increase 
of about 50 % in the metabolism rate due to contraceptive hormones, metabolic parameters for 
the group of women without hormonal contraceptive  were modified, by reducing the Michaelis-
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Menten maximum rate value by half. Thus, for the MEK model, VM1 = 2.7 mg/(h*kg0.75), for the 
1M2P model, VM1 = 15 mg/(h*kg0.75), and for the 111TCE model, VM1 = 0.21 mg/(h*kg0.75).  
Concerning phase II metabolism, Miners et al.(31) showed that glucuronidation was induced in 
women using oral contraceptives. In the previous human volunteer study(14), women on hormonal 
contraceptives appeared to excrete a higher fraction as conjugate than those not taking hormonal 
contraception, indicating also that sex hormones levels may influence the enzyme activity of 
phase II reactions but differences were not statistically significant due to a high variability. Based 
on Miners et al.(31) observations, the Michaelis-Menten maximum rate value for conjugation was 
reduced by 45 % for the group of women without hormonal contraceptive. Thus, for the 1M2P 
model, VM2 = 0.11 mg/(h*kg0.75). 
 
Figures 2 to 5 illustrate the comparison of experimental data with simulated data for the 
different urinary indicators of exposure considered.  
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FIGURE 2. Comparison of experimental data with simulated data for urinary MEK obtained (a) in men and (b) in 
women. Urinary MEK concentrations as function of time were obtained after 6 hours of exposure to 99.15 ( 5.29) 
ppm MEK. Arithmetic mean values ( SD: standard deviation) are indicated; n = number of volunteers. 
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FIGURE 3. Comparison of experimental data with simulated data for urinary free 1M2P obtained (a) in men and (b) 
in women. Urinary free 1M2P concentrations as function of time were obtained after 6 hours of exposure to 53.22 ( 
3.04) ppm of 1M2P. Arithmetic mean values ( SD: standard deviation) are indicated; n = number of volunteers. 
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FIGURE 4. Comparison of experimental data with simulated data for urinary total 1M2P obtained (a) in men and (b) 
in women. Urinary total 1M2P concentrations as function of time were obtained after 6 hours of exposure to 53.22 ( 
3.04) ppm of 1M2P. Arithmetic mean values ( SD: standard deviation) are indicated; n = number of volunteers. 
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FIGURE 5. Comparison of experimental data with simulated data for urinary TCE obtained (a) in men and (b) in 
women. Urinary TCE concentrations as function of time were obtained after 6 hours of exposure to 102.55 ( 3.19) 
ppm of 111TCE. Arithmetic mean values ( SD: standard deviation) are indicated; n = number of volunteers. 
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Table V summarizes the experimental data obtained at the end of exposure in the human 
volunteer study(14) on one hand and the simulated values obtained at the end of exposure within 
the TK models on the other hand, for the considered biological determinants. 
 
TABLE V. Summary of the different biomarkers values (experimental and simulated) obtained at the end of 
exposure. Arithmetic mean values ( SD: standard deviation) are indicated for experimental data.  
 
 Biological indicators levels at the end of exposure 
 
CMEK,urine  
[mg/l] 
Cfree1M2P,urine  
[mg/l] 
Ctotal1M2P,urine  
[mg/l] 
CTCE,urine  
[mg/g creatinine] 
Men     
   Experiment 1.00 ± 0.13 2.99 ± 0.49 4.36 ± 1.76 5.42 ± 2.19 
Simulation 1.07 2.72 4.06 6.76 
 
Women with hormonal contraceptive 
    
Experiment 0.97 ± 0.23 2.61 ± 0.96 4.17 ± 1.58 6.46 ± 1.73 
Simulation 1.04 2.81 4.21 6.31 
 
Women without hormonal contraceptive 
    
Experiment 1.44 ± 0.76 3.81 ± 1.68 4.85 ± 0.97 3.77 ± 1.24 
Simulation  
(same metabolic parameters) 
1.03 2.83 4.21 5.76 
Simulation  
(modified metabolic parameters) 
1.42 4.46 5.47 2.99 
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Finally, the goodness-of-fit between experimental data and simulated data can be assessed by 
linear regression analysis assuming that the slope yields the value of 1 in the case of perfect 
agreement. Thus a scatterplot of the predicted data versus the observed ones (see Figure 6) 
suggests that the toxicokinetic models seem adequate for the three studied substances, at least for 
the values obtained during exposure. During the elimination phase, the models show less 
agreement, especially for MEK and free 1M2P in urine.  
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FIGURE 6. Predicted data versus experimental data for the studied urinary biomarkers of exposure. Linear 
regression has been done for data obtained during exposure to the solvent (0 to 6 hours) on one hand and for data 
obtained during the elimination phase (6 to 24 hours) on the other hand. 
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In a second step, simulations were done for estimating the urinary levels of the different 
biological biomarkers when workers were exposed during 8 hours per day, 5 days per week, at a 
50 W work load, to the threshold limit value of each solvent studied. Predictions are illustrated in 
Figure 7 for each solvent and for each studied human volunteer group.  
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FIGURE 7. Simulation of mean urinary levels of biological indicators of exposure in workers (by considering men, 
women with and without hormonal contraceptive) exposed during 8 hours per day, 5 days per week, at a 50 W work 
load, to the threshold limit value of (a) MEK, (b) 1M2P and (c) 111TCE  
 
 
From these models, it is also possible to get predictions for the concentrations of the studied 
substances in other biological matrices or tissues, as for example in blood (corresponding to the 
central compartment of the model) or in fat (corresponding to the peripheral compartment of the 
model).  
When taking the same simulation conditions as just before, the model predicted a maximal 
blood concentration of 7.8 mg/l for MEK and of 21.1 mg/l for total 1M2P in men as in women 
with hormonal contraceptives. In women without hormonal contraceptives, the predicted levels 
corresponded to 11.1 mg/l for MEK and 34.5 mg/l for total 1M2P.  As for the urinary biomarkers 
of exposure, blood levels are about 50 % higher in women without hormonal contraceptives. In 
the previous human volunteer study(14), blood levels for MEK and 1M2P have not been measured 
and thus, there are no experimental data for confirming the observed differences among the 
predicted values.  
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In the case of 111TCE, the model predicted, after 8 hours of exposure, a maximal blood 
concentration of 0.62 mg/l in each group of volunteer (the value is equal to 0.28 mg/l when 
running the model under the same exposure conditions as in the human volunteer study), showing 
no differences between them. This observation can in fact be confirmed by the experimental data 
obtained in the previous human volunteer study.(14) End-exposure values obtained for men, 
women with and without hormonal contraceptive, respectively were 362.97 (± 91.05), 306.53 (± 
152.27) and 371.13 (± 240.64) µg/l, with no statistically significant differences between the 
different groups.  
111TCE levels predicted in fat (see Figure 8) were equal to 0.13 mg/l in men, 0.07 mg/l in 
women with hormonal contraceptives and 0.06 mg/l in those without. Here the observed 
differences were of course related to the differences in body fat among the different groups of 
volunteers, indicating that women have a two-fold higher body fat value than men.  
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FIGURE 8. Simulation of mean 111TCE fat levels in workers (by considering men, women with and without 
hormonal contraceptive) exposed during 8 hours per day, 5 days per week, at a 50 W work load, to the threshold 
limit value of 111TCE  
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DISCUSSION 
Our results showed that it was possible to use an existing generic toxicokinetic model for other 
compounds by adapting it to every studied organic solvent. In fact, most of the simulation results 
showed good agreement with the experimental data obtained.  
When looking at the measured urinary MEK concentrations obtained by Liira et al.(17) and 
when taking into account the fact that MEK kinetics are dose-dependent,(18) our experimental 
data match those within the literature. Devanthéry et al.(32) measured urinary 1M2P 
concentrations in human volunteers at an exposure concentration, amongst others, 50 ppm, which 
were of the same order of magnitude as the experimental data of this study. The relevant 
literature available for 111TCE is abundant. As a matter of fact, Lu et al.(33) found fifteen 
published PBPK models in rats and humans, and among the eleven studies selected for 
experimental data, four were studied in human volunteers. The more relevant study, performed in 
similar exposure conditions, was a human volunteer study carried out by Monster et al.(34). The 
measured urinary excretions of the 111TCE’s metabolites found in this study were similar to our 
results.  
When simulations were performed with the same values for the metabolic parameters but with 
the data measured for the female human volunteer groups, results were quite similar to those 
obtained for men, indicating that physiological parameters as body weight, body height and body 
fat, have a rather weak influence on the urinary levels of the different biological indicators of 
exposure. Women with hormonal contraceptive showed values close to the ones determined for 
men, which was not the case for women without hormonal contraceptive. 
Thus, metabolic parameters were modified for the latter ones by reducing the Michaelis-
Menten maximum rate value by half for each solvent, with the assumption that the differences 
observed between the human volunteers groups are due to an effect on the CYP2E1 activity by 
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exogenous hormones(14), which suggested that there was a mean increase of about 50 % in the 
metabolism rate due to contraceptive hormones. Simulations with the modified metabolic 
parameters values resulted in a better agreement with the experimental data obtained for women 
without hormonal contraceptive. Above all, these simulations showed that metabolic parameters 
had much larger effects than the physiological parameters on the studied biological determinants. 
Physiological parameters are expressed in function of body weight and thus take into account 
possible male/female differences in pulmonary ventilation, cardiac output and organ blood flows, 
generally due to body size. Moreover the fact that differences are observed between women 
underlines Gochfeld’s hypothesis(13) that toxicokinetic differences mainly involve metabolism. 
The author also stated that there is still a tendency to believe that most sex differences relate to 
morphology and body size. He pointed out that the differences in susceptibility between men and 
women need to be incorporated in risk assessments, as most toxicological studies still focus on 
only one sex.  
The predictive simulations done over a week within working conditions indicated that 
exposure for women without hormonal contraceptive can be overestimated in the case of MEK 
and 1M2P but underestimated in the case of 111TCE. For the latter, Truchon et al.(9) have 
estimated the extent of the variability for its biomarkers, indicating that TCE urinary levels can 
vary from 11 to 80 mg/l due to biological variability, without taking into account differences due 
sex and age. Urinary TCE values in this study were adjusted by creatinine to correct for variable 
dilutions among spot urine samples. Results would be lower when expressed as mg/l. Thus, in 
this case, sex differences could contribute to enlarge the extent of the variability for the 
considered biological indicator. 
Moreover, the urinary levels in biomarkers predicted with our TK models were compared to 
the existing BEIs. Interestingly, urinary levels following TLV exposures to MEK and 1M2P 
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were, in a general way, found to be higher than the current BEI, suggesting that work load can 
have a significant impact on biological exposure indicators.(35) 
The main limitation of the models concerns the elimination phase of the urinary biomarkers of 
exposure, mainly for urinary MEK and urinary 1M2P (free and total). In fact agreement between 
observed and predicted values is weaker and this can lead to an over- or underestimation of the 
corresponding exposure level. In the case of MEK, an explanation could be the metabolic 
saturation, as in humans it begins at relatively low levels of exposure(18), and greater amounts of 
MEK would be expected to be excreted via the kidney. For 1M2P, the high variability in 
glucuronidation observed in the previous human volunteer study(14) could explain the differences 
observed between experimental and simulated data.  
But a predictive model should be used as a further tool in exposure assessment. BEIs are 
guidelines established when a worker is exposed during a whole workshift to the TLV value of 
the considered chemical. When comparing with guidelines, the most important is to know about 
biomarkers levels at the end of exposure. Thus sampling time of a biological fluid  plays a crucial 
role when evaluating a worker’s exposure to a chemical. From this point, the exposure level can 
be extrapolated by simulation. Then an average value of the exposure level over the whole 
workshift should be compared with the corresponding threshold limit value. 
In conclusion, a general and simple toxicokinetic model, adapted for three well known organic 
solvents, allowed us to show that metabolic parameters can have an important impact on the 
urinary levels of the corresponding biomarkers. Indeed, experimental data pointed out that for 
same exposure conditions, men and women can show a difference of 50 % among the urinary 
biological indicators levels. Moreover, when running the models by simulating industrial 
working conditions, these differences could be even more pronounced. These observations give 
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evidence of an interindividual variability, an aspect that should have its place in the approaches 
for setting limits of occupational exposure. 
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4 General discussion 
 
The purpose of this study was to evaluate individual differences in chemical disposition due to 
age and sex. The results of this study suggest that age and sex can have an impact on urinary 
levels of biological indicators of exposure, which can be explained by differences in the 
toxicokinetics of the chemical agents. Overall literature review on toxicokinetic differences due 
to age and sex showed a list of parameters that may contribute to a modified response of the 
organism when exposed to a substance. Some were extensively described, like physiological data 
for example, while others were inconsistent, which was the case for metabolic parameters, or 
presented gaps.  
Thomson et al. (2009) carried out a thorough literature review about physiological data for 
healthy and health-impaired elderly. They concluded that the overall data gap across the age 
groups concerned particularly tissue and blood composition data. Moreover physiological 
measurements in health-impaired older adults were particularly limited. For metabolic functions, 
they suggested that the lack of such data is not crucial since the decline in metabolic activity in 
elderly persons might be more a consequence of the decrease in liver blood flow and weight than 
a change in enzyme activity which was also assumed in the first part of this project. The tentative 
description of age differences in biological monitoring of exposure using existing TK models, 
developed by Pierrehumbert et al. (2002) for a series of chemical substances, indicated that some 
chemicals seemed to be hardly affected while others showed large changes in the levels of 
biological determinants. Excretion functions seemed to play a key role in the differences 
observed when simulating occupational exposures for elderly individuals. But parameters as 
metabolism, storage, long half-lives, hydrophilic or lipophilic property of a chemical, which are 
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often chemical-specific, also It is therefore essential to study and describe not only some specific 
chemicals, but also the mechanism underlying those changes in order to be able to forecast 
changes for new chemicals.  
Regarding toxicokinetic differences due to sex, Gochfeld (2007) presented that these changes 
appear to be about 20 %, mostly in the direction of increased female susceptibility due to body 
composition. However, he also mentioned that some of the metabolic differences reach an order 
of twofold. The author stated that there is still a tendency to believe that most sex differences are 
related to morphology and body size. The main part of this project consisted to quantify the 
influence of sex on urinary levels of biomarkers of exposure. The human volunteer study also 
involved an important work in analysis. One of the analytical methods, the determination of 
urinary 1M2P, had been improved and was calibrated through the new experimental data. In 
comparison to the former procedure, which included a solid-phase extraction and derivatization 
before analysis by gas chromatography coupled to a flame ionization detector, the alternative one 
corresponded to the simple headspace technique, which improved the sensitivity of analysis and 
lowered the limit of detection. The urinary levels measured for all the studied biological 
indicators of exposure showed that there exist differences between men and women when 
exposed to organic solvents which could be explained not only by physiological differences but 
also by differences in CYP2E1 enzyme activity. The latter one seemed to be “estrogen-sensitive” 
showing an decrease in activity when estrogen levels are high (Kennedy, 2008). When combining 
this hypothesis with the results observed, this study suggests that the use of hormonal 
contraceptive like the combined contraceptive pill increases CYP2E1 activity as the level in free 
estradiol is lower in women taking the contraceptive pill (Bjørnerem et al., 2004) than in women 
without any hormonal contraceptive. The only comparable study is the one conducted by 
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Ernstgård et al. (2003a,b). They studied two organic solvents and had a similar approach, with 
the difference of exposing human volunteers during two hours of light physical exercise (50 W). 
Their conclusion was that small differences due to sex had been observed, mainly due to body 
build. When looking at the measured values after two hours of exposure obtained in this study, 
the same conclusion could be deduced. Thus exposure time is a determinant factor for 
underlining toxicokinetic differences due to sex in biological monitoring of exposure.  
The whole set of experimental data obtained from the human volunteer study were used in the 
last part of this project. A general and simple toxicokinetic model (Pierrehumbert et al., 2002), 
adapted for the three studied organic solvents, allowed to show that metabolic parameters can 
have an important impact on the urinary levels of the corresponding biomarkers. When 
simulations were performed with the same values for the metabolic parameters but with the data 
measured for the female human volunteer groups, results were quite similar to those obtained for 
men, indicating that physiological parameters have a rather weak influence on the urinary levels 
of the different biological indicators of exposure. Women with hormonal contraceptive showed 
values close to the ones determined for men, which was not the case for women without 
hormonal contraceptive. Thus, metabolic parameters were modified for the latter ones by 
reducing the Michaelis-Menten maximum rate value by half for each solvent, with the 
assumption that the differences observed between the human volunteers groups are due to the 
effect on the CYP2E1 activity by exogenous hormones. Simulations with the modified metabolic 
parameters values resulted in a better agreement with the experimental data obtained for women 
without hormonal contraceptive. Moreover the fact that differences were observed between 
women underlines the idea that toxicokinetic differences mainly involve metabolism, affirmed by 
Gochfeld (2007).  
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Another purpose was to explore genetic polymorphism in CYP2E1. The genotype of the human 
volunteers showed that a minority was carrier of the studied variant alleles, which were 
CYP2E1*5 and CYP2E1*6. Literature on this subject is very inconsistent. Prieto-Castello et al. 
(2010) observed for example a reduced activity of CYP2E1 in the presence of CYP2E1*5 and 
CYP2E1*6 variant alleles. The results in this study had a tendency to show the opposite, which 
could be explained by the very low number of carriers of the variant allele or by an eventual high 
interindividual variability in CYP2E1 enzyme activity (Bebia et al., 2004).  
In conclusion, this study showed that differences due to age could have an important impact on 
urinary levels of biological indicators of exposure in function of the chemical considered. But the 
present simulations did not take into account the apparition of various diseases with age and the 
increase use of medications, aspects that would probably enhance those observed differences. 
Disease is in fact a major source of variability in drug response (Löf and Johanson, 1998). The 
present predictions should therefore be considered as minima to be expected. This study also 
suggests that differences due to sex could have an important effect on urinary levels of biological 
determinants. Indeed, experimental data pointed out that for same exposure conditions, men and 
women can show a difference of 50 % among the urinary biological indicators levels. Actually 
statistically significant differences were particularly observed between women taking a hormonal 
contraceptive and those without. Consequently differences should also exist between men and 
women. Moreover the effect due to the hormonal contraceptive suggests that the use of 
menopausal hormone therapy in elderly women could have a considerable impact on the 
toxicokinetics of chemical agents.  
Overall these observations give evidence of a major interindividual variability, an aspect that 
should have its place in the approaches for setting limits of occupational exposure. 
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5 Perspectives 
 
This study had a special experimental part as human volunteers have participated to it. The 
experimental protocol followed severe rules and conditions, which made that the whole study 
focused on a healthy population. Hormonal contraceptive were accepted because it concerns a 
majority of women today and the recruitment period showed that it was actually difficult to find 
young women without hormonal contraception. Results showed finally that exogenous hormones 
can have an effect on the metabolism of organic solvents, which suggest that menopausal 
hormone therapy, which also concerns a lot of women, could be a subject of concern in the field 
of occupational health. Moreover, in a general way, this study underlines that the use of 
medication has to be taken into account in the assessment of occupational exposure. The same is 
true for physical activity. Indeed, participants were exposed to the studied substances at rest and 
simulations within working conditions showed that physical activity can have an important effect 
on urinary levels of biomarkers.  
Thus, the results of this project mainly showed that the relation between external and internal 
exposure to a chemical is not that simple. For same exposure conditions, the interindividual 
variability can have an important impact on the levels of biological determinants, which leads to 
think that the approach to fix BEIs on basis of a direct correlation with the TLVs is not 
appropriate. More information, if possible, about the different BEIs should be given, as for 
example an annotation when parameters like age, sex or the use of medications can have an 
important effect on the levels of the biomarkers of exposure.  
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For the occupational hygienist, the results of the project underline that it is important to couple 
biological monitoring with air sampling. In fact, the only value of a biological indicator of 
exposure could lead to an under- or an overestimation of the occupational exposure, which can 
have a consequence on the workplace risk assessment. 
For the occupational physician, the results of the study emphasize that the interpretation of 
biological monitoring results needs to take into account interindividual variability. For an elder 
worker, it is important to follow his health status, in particular his renal functions as these could 
have an influence on the elimination of the chemical compounds. Otherwise, male/female 
differences as the use of medications, among others hormonal treatments, should be taken into 
account when evaluating the occupational exposure of a person upon biological monitoring 
results. In this project, it has been showed that not only physiological parameters (for example 
body fat) can influence urinary levels of several biological indicators of exposure but also 
exogenous hormones. The use of hormonal contraceptives can have an effect of about 50 % on 
the urinary levels of several biomarkers of exposure, a magnitude that can have an important 
consequence in the interpretation of a biomonitoring result when comparing it to a BEI.  
Furthermore, in order to take into account uncertainty around the different parameters used in the 
TK models, it would be possible to develop them further as population models within a Bayesian 
framework.  
Finally, the main objective of this study was to evaluate the influence of age and sex on the 
toxicokinetics of solvents. Another concern would be to investigate the influence of such 
parameters on the toxicodynamics of solvents.  
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Annex I – Experimental data 
 
Table 1. Summary of the controlled human exposure sessions performed at the IST 
 
N° expo Date Solvant Nvolunteers
Cchamber,average 
[ppm] 
1 04.12.2007 MEK 2 88.6 
2 11.12.2007 MEK 2 101.6 
3 18.12.2007 1M2P 2 52.5 
4 15.01.2008 1M2P 2 48.1 
5 29.01.2008 STY 3 10.1 
6 05.02.2008 STY 2 10.1 
7 12.02.2008 1M2P 2 51.7 
8 26.02.2008 111TCE 2 99.2 
9 04.03.2008 111TCE 3 99.9 
10 11.03.2008 STY 1 10.8 
11 18.03.2008 MEK 2 100 
12 26.03.2008 111TCE 1 104.9 
13 07.07.2008 1M2P 1 55.2 
14 22.07.2008 MEK 1 52.3 
15 05.08.2008 111TCE 1 102.1 
16 30.09.2008 STY 1 9.3 
17 13.01.2009 1M2P 3 60.2 
18 15.01.2009 1M2P 3 59.2 
19 27.01.2009 MEK 3 101.7 
20 29.01.2009 MEK 3 103.1 
21 03.02.2009 MEK 2 101.6 
22 10.02.2009 111TCE 1 111.5 
23 12.02.2009 1M2P 1 60.1 
24 17.02.2009 MEK 3 100.7 
25 19.02.2009 111TCE 2 110.4 
26 03.03.2009 1M2P 1 55.2 
27 05.03.2009 1M2P 1 52.3 
28 10.03.2009 111TCE 2 102.1 
29 12.03.2009 1M2P 3 54.5 
30 17.03.2009 111TCE 3 101.6 
31 24.03.2009 MEK 2 104.9 
32 26.03.2009 111TCE 4 103.2 
33 06.04.2009 111TCE 1 105.5 
34 07.04.2009 1M2P 3 57 
35 23.04.2009 MEK 2 105.6 
36 29.04.2009 MEK 3 97.4 
37 07.05.2009 1M2P 1 52.1 
38 13.05.2009 1M2P 1 54.2 
39 19.05.2009 1M2P 1 52.3 
40 28.05.2009 111TCE 4 105.3 
41 16.06.2009 MEK 1 93 
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Table 2. Characteristics of the human volunteers with their CYP2E1 genotypes  
 
Volunteer Sex 
Age 
[years] 
BW 
[kg] 
BH 
[cm] BMI
BF 
[%] Cyp*5 Cyp*6
Hormonal 
contraceptive 
1 man 20 75 184 22.15 11.7 c1/c1 TT   
2 man 23 67 176 21.63 10.1 c1/c1 TT   
3 man 25 64 179 19.97 6.2 c1/c1 TA   
4 man 19 69 176 22.28 6.4 c1/c1 TT   
5 man 24 62 173 20.72 9.4 c1/c1 TT   
6 man 22 64 175 20.90 11.5 c1/c1 TT   
7 man 20 74 178 23.36 15.7 c1/c1 TT   
8 man 22 60 175 19.59 9.7 c1/c1 TT   
9 man 25 77 179 24.03 8.7 c1/c1 TT   
10 man 24 95 180 28.70 24 c1/c1 TT   
                    
11 woman 24 68 169 23.81 14.3 c1/c1 TT YES 
12 woman 25 59 173 19.71 18.7 c1/c1 TT YES 
13 woman 23 53 163 19.95 20.2 c1/c1 TT YES 
14 woman 23 51 165 18.73 14.3 c1/c1 TT YES 
15 woman 24 54 167 19.36 22.4 c1/c1 TT YES 
16 woman 19 53 163 19.95 15.2 c1/c1 TT YES 
17 woman 25 64 165 23.51 20.7 c1/c1 TA YES 
18 woman 21 62 172 20.96 19.3 c1/c1 TT YES 
19 woman 21 72 163 27.10 29.1 c1/c1 TT YES 
20 woman 21 65 170 22.49 23.8 c1/c1 TT YES 
21 woman 21 67 163 25.22 28.7 c1/c1 TT NO 
22 woman 26 66 163 24.84 30.2 c1/c2 TA NO 
23 woman 22 58 165 21.30 21.1 c1/c1 TT NO 
24 woman 22 54 160 21.09 14.7 c1/c1 TT NO 
25 woman 31 83 166 30.12 38.2 c1/c1 TA NO 
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Table 3. Summary of MEK concentrations in urine for every participant 
 
Volunteer CMEK,0h [mg/l] CMEK,2h [mg/l] CMEK,4h [mg/l] CMEK,6h [mg/l] CMEK,8h [mg/l] CMEK,10h [mg/l] CMEK,12h [mg/l] CMEK,14h [mg/l]CMEK,24h [mg/l]
1 0.08 0.85 1.04 0.96 0.3 0.11 0.04 0.06
2 0.03 1 1.13 0.99 0.23 0.14 0.08 0.06
3 0.11 0.79 1.01 0.93 0.21 0.09 0.04
4 0.05 0.58 1.04 1.04 0.09 0.02 0.06
5 - 0.94 1.22 1.01 0.36 0.09 0.14 0.06
6 0.09 0.82 0.9 0.99 0.39 0.1 0.22 0.15
7 0.09 0.9 1.06 0.88 0.24 0.07
8 0.06 0.9 1.15 1.05 0.3 0.04 0.06
9 0.08 0.76 1.06 1.32 0.55 0.08 0.05
10 0.1 0.66 0.95 0.87 0.52 0.04
11 0.18 1.07 1.35 1.26 0.14 0.1 0.11
12 0.06 0.65 0.72 0.79 0.71
13 0.1 0.83 0.99 0.96 0.12 0.05 0.05
14 0.05 1.15 1.65 1.49 0.21 0.13 0.1 0.06
15 0.08 0.83 0.96 0.92 0.14 0.07 0.08
16 0.13 0.88 1 0.92 0.18 0.1 0.05
17 0 0.59 0.79 0.75 0.09 0.05 0
18 0.11 0.87 1.01 0.9 0.46
19 - 0.8 0.79 0.77 0.9 0.09 0.13
20 0 0.63 0.89 0.95 0.43 0.09 0.08
21 - 0.81 1.14 1.09 0.17 0.14 0.09
22 0.06 0.99 1.28 1.35 0.65 0.09 0.05 0.06
23 - 1.13 2.05 2.72 2.73 0.5 0.12
24 - 0.67 1.16 1.33 0.44 0.15 0.07
25 - 0.57 0.72 0.73 0.23 0.15 0.07
Moyf emme 0.08 0.83 1.10 1.13 0.82 0.19 0.08 0.10 0.07
SDf emme 0.06 0.19 0.37 0.50 0.80 0.13 0.04 0.03 0.03
Moyf emme,av ec 0.08 0.83 1.02 0.97 0.63 0.15 0.08 0.09 0.07
SDf emme,av ec 0.06 0.18 0.28 0.23 0.22 0.04 0.05 0.01 0.04
Moyf emme,sans 0.06 0.83 1.27 1.44 1.01 0.34 0.09 0.12 0.08
SDf emme,sans 0.23 0.48 0.76 1.16 0.23 0.05 0.02
Moyhomme 0.08 0.82 1.06 1.00 0.36 0.24 0.11 0.10 0.07
SDhomme 0.03 0.13 0.09 0.13 0.11 0.17 0.08 0.07 0.03  
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Table 4. Summary of free 1M2P concentrations in urine for every participant 
 
Volunteer C1M2P,0h [mg/l] C1M2P,2h [mg/l] C1M2P,4h [mg/l] C1M2P,6h [mg/l] C1M2P,8h [mg/l] C1M2P,10h [mg/l] C1M2P,12h [mg/l] C1M2P,14h [mg/l] C1M2P,16h [mg/l] C1M2P,20h [mg/l] C1M2P,24h [mg/l]
1 0 1.41 2.55 2.57 1.62 0 0 0 0 0
2 0 1.29 2.26 3.21 2.22 0.31 0 0
3 0 1.42 2.29 3.11 1.18 0.28 0 0
4 0.11 0.85 2.33 2.68 2.32 0.14 0.09
5 0 1.73 2.71 3.69 1 0.29 0 0 0
6 0 1.73 3.07 3.33 1.06 0.37 0.19 0 0
7 0 1.8 2.36 3.37 3.05 0.51 0
8 0 1.52 2.52 2.79 1.56 0.42 0.14 0 0
9 0 0.93 2.08 2.12 0.33 0
10 0 1.85 2.23 - 0 0
11 0 1.02 2.25 2.71 2.05 0.63 0.35 0 0 0
12 0.12 1.11 1.88 2.42 0.94 0.28 0.29 0
13 0 2.91 2.7 2.77 0.34 0.23 0.2 0
14 0.18 1.91 3.84 3.88 1.54 0.39 0.17 0.14
15 0 1.4 1.52 1.22 0.55 0 0
16 0 1.37 1.88 4.16 0.83 0 0
17 0 1.79 2.56 3.05 0.69 0.16 0 0 0
18 0 1.85 2.31 2.67 1.68 0.34 0 0
19 0.19 1.81 2.05 1.44 0.15 0 0
20 0 1.9 2.32 1.78 0.72 0
21 0 2.09 2.97 2.35 0.27 0 0
22 0 2.39 4.38 4.07 3.5 1.71 0.19 0
23 0.35 1.06 3.48 3.15 6.2 1.24 0.16
24 0 1.72 3.34 6.6 4.26 0.83 0
25 - 1.79 2.67 2.86 1.12 0.19 0
Moyf emme 0.06 1.74 2.68 3.01 2.88 0.67 0.45 0.17 0.07 0.03 0.01
SDf emme 0.11 0.51 0.80 1.32 1.87 0.42 0.45 0.16 0.10 0.07 0.04
Moyf emme,av ec 0.05 1.71 2.33 2.61 1.55 0.51 0.29 0.21 0.04 0.00 0.02
SDf emme,av ec 0.08 0.54 0.63 0.96 0.46 0.20 0.24 0.19 0.09 0.00 0.05
Moyf emme,sans 0.09 1.81 3.37 3.81 4.65 0.98 1.24 0.10 0.19 0.08 0.00
SDf emme,sans 0.18 0.50 0.65 1.68 1.39 0.60 0.13 0.11 0.00
Moyhomme 0.01 1.45 2.44 2.99 1.99 0.62 0.28 0.12 0.00 0.00 0.01
SDhomme 0.03 0.35 0.29 0.49 0.67 0.50 0.16 0.13 0.00 0.03  
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Table 5. Summary of total 1M2P concentrations in urine for every participant 
 
Volunteer C1M2P,0h [mg/l] C1M2P,2h [mg/l] C1M2P,4h [mg/l] C1M2P,6h [mg/l] C1M2P,8h [mg/l] C1M2P,10h [mg/l] C1M2P,12h [mg/l] C1M2P,14h [mg/l] C1M2P,16h [mg/l] C1M2P,20h [mg/l] C1M2P,24h [mg/l]
1 0 1.57 2.74 4.21 2.15 0.23 0 0 0 0
2 0 1.82 2.88 4.1 3.16 1.58 0.77 0
3 0 1.8 3.52 4.46 1.39 0.46 0.22 0.21
4 0.2 1.01 3.03 2.82 2.69 0.25 0.23
5 0 2.36 3.88 8.8 2.21 0.22 0 0 0
6 0 1.85 3.18 3.49 1.52 0.44 0.37 0 0
7 0 2.21 3.15 4.14 3.37 0.81 0
8 0 1.89 3.37 4.2 2.51 0.75 0.34 0.19 0
9 0 1.32 2.57 2.98 0.55 0.17
10 0.12 2.31 2.35 - 0.3 0
11 0.22 1.5 2.07 2.67 2.12 1.01 0.49 0.17 0.25 0
12 0.38 1.71 2.81 3.28 1.46 0.6 0.63 0
13 0.26 3.19 3.07 5.87 0.98 0.23 0.36 0.25
14 0.31 1.77 4.73 6.88 5.39 1.75 0.38 0.49
15 0 3.02 2.78 4.19 1.35 0.23 0
16 0 1.8 1.89 2.85 1.86 0.25 0
17 0 1.85 2.66 6.1 0.93 0.28 0.15 0.1 0
18 0 2.03 2.39 3.83 2.26 0.65 0 0
19 0.27 1.92 3.54 3.65 0.8 0 0
20 0 2.66 3.06 2.37 1.38 0.22
21 0 2.68 3.31 4.89 0.29 0.32 0.28
22 0 2.95 4.67 4.54 4.25 3.1 0.42 0.31
23 0.41 1.49 4.43 3.69 4.9 1.86 0.31
24 0 1.61 3.46 6.37 6.86 1.28 0.43
25 - 2.13 3.13 4.78 2.21 0.64 0
Moyf emme 0.13 2.15 3.20 4.40 3.89 1.33 0.82 0.46 0.23 0.22 0.11
SDf emme 0.16 0.58 0.87 1.41 2.00 0.79 0.67 0.18 0.15 0.15 0.17
Moyf emme,av ec 0.14 2.15 2.90 4.17 2.81 1.14 0.61 0.45 0.19 0.14 0.08
SDf emme,av ec 0.16 0.59 0.81 1.58 1.76 0.47 0.48 0.20 0.13 0.12 0.17
Moyf emme,sans 0.10 2.17 3.80 4.85 5.34 1.72 1.86 0.48 0.42 0.37 0.20
SDf emme,sans 0.21 0.64 0.70 0.97 1.36 1.21 0.23 0.08 0.17
Moyhomme 0.03 1.81 3.07 4.36 2.55 1.10 0.56 0.23 0.20 0.00 0.06
SDhomme 0.07 0.43 0.46 1.76 0.72 0.77 0.53 0.14 0.30 0.10  
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Table 6. Summary of TCE concentrations in urine for every participant 
 
Volunteer CTCE,0h [mg/l] CTCE,2h [mg/l] CTCE,4h [mg/l] CTCE,6h [mg/l] CTCE,8h [mg/l] CTCE,10h [mg/l] CTCE,12h [mg/l] CTCE,14h [mg/l] CTCE,16h [mg/l] CTCE,20h [mg/l] CTCE,24h [mg/l]
1 - 0.12 1.37 6.43 3.64 0.88 5.59 1.19 2.59
2 0 0.53 2.27 5.91 10.88 9.5 8.89 4.68
3 0 0.35 0.96 6.3 0.24 2.43
4 0.56 0.95 2.52 5.67 3.19 6.63
5 0 2.14 4.31 5.36 5.39 2.18 2.89 3.83
6 0 0.93 2.55 3.55 2.5 5.43 4.75 3.1
7 0 0.62 1.13 6.76 8.26 5.23
8 0.35 1.05 1.13 9.59 5.3 4.68 5.63 6.59
9 0 1.16 4.59 5.97 1.38 4.33 3.82
10 0.54 0.27 0.74 1.05 1.32 6.27 5.67
11 0.19 0.31 1.65 2.33 2.69 2.28 2 4.86
12 - - - - - - - - - - -
13 0.2 0.48 2.16 3.3 9.79 8.94 7.21
14 0 0.4 1.76 2.77 11.63 5 1.17 1.39
15 0 0.19 - 4.09 4.31 6.8
16 0 0.83 2.27 3.03 10.44 6.34 3.2
17 0.11 0.54 1.02 2.91 5.34 1.78 3.54 8.14
18 0 1.13 2.21 4.73 9.95 2.1 1.48 0.91 3.93 5.33
19 0 0.67 2.73 5.46 7.92 11.08 7.37
20 0 0.64 2.27 5.82 3.99 3.22 3.44
21 0 0.99 0.69 2.25 4.25 1.25 1.47
22 0.05 0.85 1.01 3.41 1.53 3.83 3.51 5.85
23 0 0.13 0.28 0.41 0.88 2.85 0.57 1.59
24 0 - 1.42 3.06 5.84 1.79 2.32
25 - 0.35 0.97 1.32 2.7 1.02 1.7
Moyf emme 0.04 0.58 1.57 3.21 4.59 6.95 3.92 3.21 1.04 3.74 4.33
SDf emme 0.07 0.31 0.74 1.48 3.31 3.64 3.59 2.46 0.18 0.28 2.47
Moyf emme,av e 0.06 0.58 2.01 3.83 5.95 10.67 4.72 4.16 1.04 3.74 5.30
SDf emme,av ec 0.09 0.28 0.52 1.26 2.89 0.86 4.02 2.69 0.18 0.28 2.28
Moyf emme,sans 0.01 0.58 0.87 2.09 1.21 4.16 1.94 1.78 2.59
SDf emme,sans 0.03 0.41 0.42 1.24 0.46 1.30 1.29 1.26 1.85
Moyhomme 0.16 0.81 2.16 5.66 4.74 5.44 4.32 4.49 4.42 1.19 4.46
SDhomme 0.25 0.58 1.38 2.20 4.51 2.70 3.43 1.21 1.40 1.55  
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Table 7. Summary of TCA concentrations in urine for every participant 
 
Volunteer CTCA,0h [mg/l] CTCA,2h [mg/l] CTCA,4h [mg/l] CTCA,6h [mg/l] CTCA,8h [mg/l] CTCA,10h [mg/l] CTCA,12h [mg/l] CTCA,14h [mg/l] CTCA,16h [mg/l] CTCA,20h [mg/l] CTCA,24h [mg/l]
1 - 0.03 0.03 0.27 0.22 0.13 0.58 0.21 0.45
2 0 0 0.02 0.08 0.24 0.18 0.3 0.62
3 0 0 0 0.07 0.09 0.13
4 0.49 0.35 0.29 0.79 0.31 0.45
5 0 0.03 0.08 0.28 0.34 0.2 0.47 0.93
6 0 0.03 0.04 0.09 0.09 0.2 0.31 0.47
7 0 0.01 0.02 0.15 0.22 0.68
8 0 0.01 0.02 0.24 0.26 0.41 0.45 0.76
9 0 0 0.02 0.05 0.01 0.15 0.08
10 0 0 0.01 0.02 0.05 0.33 0.75
11 0 0 0.04 0.08 0.1 0.13 0.27 0.51
12 - - - - - - - - - - -
13 0 0 0.03 0.16 0.31 0.68 0.66
14 0 0 0.02 0.08 0.39 0.28 0.19 0.3
15 0 0 - 0.18 0.49 0.53
16 0 0 0.03 0.08 0.84 1.18 0.62
17 0 0 0.01 0.07 0.14 0.1 0.16 0.38
18 0 0.01 0.06 0.25 0.64 0.19 0.28 0.29 0.69 1.06
19 0 0.01 0.1 0.28 0.53 0.92 1.68
20 0 0.02 0.08 0.24 0.26 0.63 0.88
21 0 0 0 0 0.03 0.03 0.02
22 0 0 0.04 0.18 0.08 0.46 0.35 0.63
23 0 0 0 0.01 0.01 0.06 0.01 0.05
24 0 - 0.06 0.21 0.9 0.58 1.42
25 - 0.02 0.06 0.13 0.54 0.29 0.7
Moyf emme
SDf emme
Moyf emme,av e 0.00 0.00 0.05 0.16 0.27 0.62 0.50 0.44 0.24 0.43 0.74
SDf emme,av ec 0.00 0.01 0.03 0.08 0.17 0.23 0.51 0.19 0.07 0.37 0.43
Moyf emme,sans 0.00 0.01 0.03 0.11 0.05 0.48 0.18 0.24 0.56
SDf emme,sans 0.01 0.03 0.10 0.05 0.36 0.27 0.57
Moyhomme 0.05 0.05 0.05 0.20 0.16 0.22 0.18 0.43 0.41 0.21 0.53
SDhomme 0.16 0.11 0.09 0.23 0.16 0.09 0.07 0.14 0.09 0.27  
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Annex II – TK models equations 
 
 
o TK model for methyl ethyl ketone 
 
 
METHOD RK4 
 
STARTTIME = 0 
STOPTIME=24 
DT = 0.02 
 
 
{Differential equations} 
 
d/dt (CENTRAL) = + AA - UEc + PtoC - CtoP - UEc - Met 
INIT CENTRAL = 0 
 
d/dt (PERIPHERAL) = - PtoC + CtoP  
INIT PERIPHERAL = 0 
 
 
{FLOWS} 
 
{Air absorption rate [mg/h]} 
AA = Cexp*Valv*BW**0.7*Rpulm 
 
{Air excretion rate from central compartment [mg/h]} 
AEc = CENTRAL*Valv*BW**0.7/(Pblood_air*Vc) 
 
{Urine excretion rate from central compartment [mg/h]} 
UEc = CENTRAL*kur*BW**0.82/Vc 
 
{Peripheral to central compartment transfer rate [mg/h]} 
PtoC = PERIPHERAL*Qp/Vp 
 
{Central to peripheral compartment transfer rate [mg/h]} 
CtoP = CENTRAL*Qp/(Vc) 
 
{Central to metabolism transfer rate [mg/h]} 
Met = CENTRAL*Clmet/Vc 
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{FUNCTIONS} 
 
 
{Total Body Water [kg]} 
 
TBW = If (Sex=0) then (-12.86+0.1757*BH+0.3331*BW)  
Else (-2.097+0.1069*BH+0.2466*BW) 
 
{Body Fat [kg]} 
 
BF = bf*BW/100 
 
{Lean Body mass [kg]} 
 
LBM = BW-BF 
 
{Alveolar ventilation [l/(h*kg^0.7)]} 
Valv = IF (TIME>6 AND TIME<18) THEN (2.1951*Qc) ELSE Qc 
 
{Apparent volume of the central compartment [l]} 
Vc = Pc_blood*FVc*BW 
 
{Apparent volume of the peripheral compartment [l]} 
Vp = Pp_c*FVp*BW 
 
{Cardiac output in central compartment [l/(h*kg^0.7)]} 
Qc = IF (TIME>6 AND TIME<18) THEN Qc50W ELSE Qcrest 
 
{Cardiac output in peripheral compartment [l/(h*kg^0.7)]} 
Qp = BFp*Qc*BW**0.7 
    
{Fraction of cardiac output in peripheral compartment [-]} 
BFp = IF (TIME>6 AND TIME<18) THEN BFp50W ELSE BFprest 
 
{Cardiac output in metabolism [l/(h*kg^0.7)]} 
Q1 = BF1*Qc*BW**0.7 
 
{Fraction of cardiac output in metabolism [-]} 
BF1 =  IF (TIME>6 AND TIME<18) THEN BF150W ELSE BF1rest 
 
{Exposition concentration [mg/l]} 
Cexp = IF TIME<6 THEN (MW*TLV/Vmol/2/1000) ELSE 0 
 
{Concentration in the central compartment [mg/l]} 
Cc = CENTRAL/Vc 
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{Concentration in the peripheral compartment [mg/l]} 
Cp = PERIPHERAL/Vp 
 
{Urine concentration in central compartment [mg/l]} 
Curc = UEc/(kur*BW**0.82) 
 
{Metabolic clearance for metabolite1 [l/h]} 
Clmet = Q1*Clmet_int/(Q1+Clmet_int) 
 
{Intrinsic metabolite clearance for metabolite1 [l/(h*kg)]} 
 
Clmet_int = VM1*BW**0.75/KM1 
 
{Urine excretion rate [l/(h*kg^0.82)]} 
kur = 1.848/1000 
 
 
 
{INPUTS} 
 
Sex = 0 {0 = man, 1 = woman} 
TLV = 200 {Treshold limit value [ppm]} 
BW = 70.7 {Bodyweight [kg]; women = 60.1 (with hormonal contraceptive) and 65.6} 
    {(without hormonal contraceptive); mean value from volunteers} 
BH = 177.5 {Bodyheight [cm]; women = 167 (with hormonal contraceptive)and 163.4}  
    {(without hormonal contraceptive); mean value from volunteers} 
bf = 11.3 {Body fat [%]; women = 19.8 (with hormonal contraceptive) and 26.6}  
   {(without hormonal contraceptive); mean value from volunteers} 
Qcrest = 18.0 {Cardiac output at rest [l/(h*kg^0.7)]} 
Qc50W = 30.8 {Cardiac output at 50 W [l/(h*kg^0.7)]} 
Rpulm = 0.558   {Pulmonary retention [-]} 
 
 
Vmol = 25.45 {Molar volume [l/mol]} 
 
{Volumes of the different compartments expressed as a fraction of BW} 
 
FVc = 1*TBW/BW  
FVp = 1*BF/BW  
 
 
{Different partition coefficients [-]} 
 
Pblood_air = 123 
Pc_blood = 0.856 
Pp_c= 1.296 
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{Michaelis-Menten maximum rate and constant [mg/(h*kg^0.75)] and [mg/l]} 
 
VM1 = 5.4 
KM1 = 1.1 
 
 
{Fraction of cardiac output in the different compartments at 50W [-]} 
 
BFp50W = 0.06 
BF150W = 0.16 
 
 
{Fraction of cardiac output in the different compartments at rest [-]} 
 
BFpREST = 0.05 
BF1REST = 0.26 
 
 
{Molecular weight of the different substances [g/mol]} 
MW = 72 
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o TK model for 1-methoxy-2-propanol 
 
 
METHOD RK4 
 
STARTTIME = 0 
STOPTIME=24 
DT = 0.02 
 
 
{Differential equations} 
 
d/dt (CENTRAL) = + AA - AEc - UEc - CtoCONJ - Met 
      INIT CENTRAL = 0 
 
 
d/dt (CONJUGUE) = + CtoCONJ - UE1  
      INIT CONJUGUE = 0 
 
 
{FLOWS} 
 
{Air absorption rate [mg/h]} 
AA = Cexp*Valv*BW**0.7*Rpulm 
 
{Air excretion rate from central compartment [mg/h]} 
AEc = CENTRAL*Valv*BW**0.7/(Pblood_air*Vc) 
 
{Urine excretion rate from central compartment [mg/h]} 
UEc = CENTRAL*kur*BW**0.82/Vc 
 
{Urine excretion rate from conjugated 1M2P compartment [mg/h]} 
UE1 = CONJUGUE*kconj  
 
{Central to conjugated 1M2P compartment transfer rate [mg/h]} 
CtoCONJ = CENTRAL*CLconj/Vc 
 
{Central to metabolism transfer rate [mg/h]} 
Met = CENTRAL*Clmet/Vc 
 
           
{FUNCTIONS} 
 
{Total Body Water [kg]} 
TBW = If (Sex = 0) then (-12.86+0.1757*BH+0.3331*BW)  
Else (-2.097+0.1069*BH+0.2466*BW) 
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{Body Fat [kg]} 
BF = bf*BW/100 
 
{Lean Body mass [kg]} 
LBM = BW-BF 
 
{Alveolar ventilation [l/(h*kg^0.7)]} 
Valv = IF (TIME>6 AND TIME<18) THEN (2.1951*Qc) ELSE Qc 
 
{Apparent volume of the central compartment [l]} 
Vc = Pc_blood*FVc*BW 
 
{Cardiac output in central compartment [l/(h*kg^0.7)]} 
Qc = IF (TIME>6 AND TIME<18) THEN Qc50W ELSE Qcrest 
 
{Cardiac output in metabolism [l/h]} 
Q1 = BF1*Qc*BW**0.7 
 
{Fraction of cardiac output in metabolism [-]} 
BF1 =  IF (TIME>6 AND TIME<18) THEN BF150W ELSE BF1rest 
 
{Exposition concentration [mg/l]} 
Cexp = IF TIME<6 THEN (MW*TLV/Vmol/2/1000) ELSE 0 
 
{Concentration in the central compartment [mg/l]} 
Cc = CENTRAL/Vc 
 
{Concentration in the conjugated 1M2P compartment [mg/l]} 
Cconj = CONJUGUE/Vc 
 
{Urine concentration from central compartment [mg/l]} 
Curc = UEc/(kur*BW**0.82) 
 
{Urine concentration from conjugated 1M2P compartment [mg/l]} 
Curconj = UE1/(kur*BW**0.82) 
 
{Total 1M2P urine concentration [mg/l]} 
Cur_total = Curc + Curconj 
 
{Metabolic clearance for metabolite [l/h]} 
Clmet = Q1*Clmet_int/(Q1+Clmet_int) 
 
{Intrinsic metabolite clearance for metabolite [l/h]} 
Clmet_int = VM1*BW^0.75/KM1 
 
{Metabolite clearance for conjugated 1M2P [l/(h*kg^0.75)]} 
Clconj = ((VM2*BW^0.75/KM2)*Qc)/((VM2*BW^0.75/KM2)+Qc) 
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{Partition coefficient [-]} 
Pc_blood = Pc_air/Pblood_air 
 
{INPUTS} 
 
Sex = 0 {0 = man, 1 = woman} 
TLV = 100 {Treshold limit value [ppm]} 
BW = 70.7 {Bodyweight [kg]; women = 60.1 (with hormonal contraceptive) and 65.6} 
    {(without hormonal contraceptive); mean value from volunteers} 
BH = 177.5 {Bodyheight [cm]; women = 167 (with hormonal contraceptive)and 163.4}  
    {(without hormonal contraceptive); mean value from volunteers} 
bf = 11.3 {Body fat [%]; women = 19.8 (with hormonal contraceptive) and 26.6}  
   {(without hormonal contraceptive); mean value from volunteers} 
Qcrest = 18.0 {Cardiac output at rest [l/(h*kg^0.7)]} 
Qc50W = 30.8 {Cardiac output at 50 W [l/(h*kg^0.7)]} 
Rpulm = 0.9     {Pulmonary retention [-]} 
Vmol = 25.45 {Molar volume [l/mol]} 
 
{Volumes of the different compartments expressed as a fraction of BW} 
FVc = 1*TBW/BW  
 
{Fraction of cardiac output in the different compartments at 50W [-]} 
BF150W = 0.16 
 
{Fraction of cardiac output in the different compartments at rest [-]} 
BF1REST = 0.26 
 
{Different partition coefficients [-]} 
Pblood_air = 12383 
Pc_air = 12280 
 
{Urinary excretion rate for conjugated 1M2P [h-1]} 
kconj = 0.20 
 
{Urine excretion rate [l/(h*kg^0.82)]} 
kur = 1.848/1000 
 
{Michaelis-Menten maximum rate and constant [mg/(h*kg^0.75)] and [mg/l]} 
 
VM1 = 30 
KM1 = 30 
 
VM2 = 0.2 
KM2 = 95 
 
{Molecular weight of the different substances [g/mol]} 
MW = 90.12 
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o TK model for 1,1,1-trichloroethane 
 
 
METHOD RK4 
 
STARTTIME = 0 
STOPTIME=24 
DT = 0.02 
 
 
{BILANS} 
 
d/dt (CENTRAL) = + AA + PtoC - AEc - CtoP - CtoM1  
INIT CENTRAL = 0 
 
d/dt (PERIPHERAL) = - PtoC + CtoP  
INIT PERIPHERAL = 0 
 
d/dt (METABOLITE_1) = + CtoM1 - UE1 - Met 
INIT METABOLITE_1 = 0 
 
 
{FLOWS} 
 
{Air absorption rate [mg/h]} 
AA = Cexp*Valv*BW**0.7*Rpulm 
 
{Air excretion rate from central compartment [mg/h]} 
AEc = CENTRAL*Valv*BW**0.7/(Pblood_air*Vc) 
 
{Urine excretion rate from metabolite1 compartment [mg/h]} 
UE1 = METABOLITE_1*ku1*BW**-0.3 
 
{Peripheral to central compartment transfer rate [mg/h]} 
PtoC = PERIPHERAL*Qp/Vp 
 
{Central to peripheral compartment transfer rate [mg/h]} 
CtoP = CENTRAL*Qp/Vc 
 
{Central to metabolite1 compartment transfer rate [mg/h]} 
CtoM1 = CENTRAL*MC1/V1 
 
{Metabolism rate from metabolite1 compartment [mg/h]} 
Met = METABOLITE_1*k_M1_M2*BW**-0.3 
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{FUNCTIONS} 
 
{Total Body Water [kg]} 
TBW = If (Sex = 0) then (-12.86+0.1757*BH+0.3331*BW)  
Else (-2.097+0.1069*BH+0.2466*BW) 
 
{Body Fat [kg]} 
BF = bf*BW/100 
 
{Lean Body mass [kg]} 
LBM = BW-BF 
 
{Molar volume [l/mol]} 
Vmol = 25.43 
 
{Alveolar ventilation [l/(h*kg^0.7)]} 
Valv = IF (TIME>6 AND TIME<18) THEN (2.1951*Qc) ELSE Qc  
 
{Apparent volume of the central compartment [l]} 
Vc = Pc_blood*FVc*BW 
 
{Apparent volume of the peripheral compartment [l]} 
Vp = Pp_c*FVp*BW 
 
{Apparent volume of the metabolite1 compartment [l]} 
V1 = P_M1_blood*FV1*BW 
 
{Cardiac output in central compartment [l/(h*kg^0.7)]} 
Qc = IF (TIME>6 AND TIME<18) THEN Qc50W ELSE Qcrest 
 
{Cardiac output in peripheral compartment [l/h]} 
Qp = BFp*Qc*BW**0.7 
    
{Fraction of cardiac output in peripheral compartment [-]} 
BFp = IF (TIME>6 AND TIME<18) THEN 0.06 ELSE 0.05 
 
{Cardiac output in metabolite1 compartment [l/h]} 
Q1 = BF1*Qc*BW**0.7 
 
{Fraction of cardiac output in metabolite1 compartment [-]} 
BF1 = IF (TIME>6 AND TIME<18) THEN 0.16 ELSE 0.26 
 
{Exposition concentration [mg/m3]} 
Cexp =  IF TIME<6 THEN (MW*TLV/Vmol/2/1000) ELSE 0 
 
{Concentration in the central compartment [mg/l]} 
Cc = CENTRAL/Vc 
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{Concentration in the peripheral compartment [mg/l]} 
Cp = PERIPHERAL/Vp 
 
{Concentration in expired air from the central compartment [ppm]} 
Cac = 1000*Vmol*AEc/(MW*Valv*BW**0.7) 
 
{Creatinine concentration in metabolite1 compartment [mg/g of creatinine]} 
Ccr1 = 1000*UE1/(kcr*BW**0.9) 
    
{Urine concentration in metabolite1 compartment [mg/l]} 
Ccu1 = UE1/(kur*BW**0.82) 
 
{Partition coefficient central compartment/blood [-]} 
Pc_blood = Pc_air/Pblood_air 
 
{Partition coefficient peripheral/central compartment [-]} 
Pp_c = Pp_air/Pc_air 
 
{Partition coefficient metabolite1 compartment/blood [-]} 
P_M1_blood = P_M1_air/Pblood_air 
 
{Creatinine excretion rate [mg/(h*kg^0.9]} 
kcr = 12.06*MWcr/1000 
 
{Urine excretion rate [l/(h*kg0.82^)]} 
kur = 1.848/1000 
 
{Intrinsic metabolite clearance for metabolite1 [l/h]} 
MCl1 = VM1*BW^0.75/KM1 
 
{Metabolic clearance for metabolite1 [l/h]} 
MC1 = Q1*MCl1/(Q1+MCl1) 
 
 
{INPUTS} 
 
Sex = 0 {0 = man; 1 = woman} 
TLV = 200 {Treshold limit value [ppm]} 
BW = 70.7 {Bodyweight [kg]; women = 60.1 (with hormonal contraceptive) and 65.6} 
    {(without hormonal contraceptive); mean value from volunteers} 
BH = 177.5 {Bodyheight [cm]; women = 167 (with hormonal contraceptive)and 163.4}  
    {(without hormonal contraceptive); mean value from volunteers} 
bf = 11.3 {Body fat [%]; women = 19.8 (with hormonal contraceptive) and 26.6}  
   {(without hormonal contraceptive); mean value from volunteers} 
Qcrest = 18.0 {Cardiac output at rest [l/(h*kg^0.7)]} 
Qc50W = 30.8 {Cardiac output at 50 W [l/(h*kg^0.7)]} 
Rpulm = 0.25 
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{Volumes of the different compartments expressed as a fraction of BW} 
 
FVc =  1*TBW/BW 
FVp = 1*BF/BW 
FV1 =   0.026 
 
{Different partition coefficients [-]} 
 
Pc_air = 2.53 
Pblood_air = 2.53 
Pp_air = 263 
P_M1_air = 8.6 
 
{Urine excretion rate constants in the different compartments [1/(h*kg^-0.3)]}  
ku1 = 0.093 
 
{Metabolic rate TCE to TCA [h-1*kg^-0.3]} 
k_M1_M2 = 0.069 
 
{Michaelis-Menten maximum rate for metabolite 1  [mg/(h*kg^0.75)]} 
VM1 = 0.42 
 
{Michaelis-Menten constants for metabolite 1  [mg/l]}  
KM1 = 5.75 
 
{Molecular weight of the different substances [g/mol]} 
MW = 133.40 
MW1 = 149.40 
MWcr = 113.12 
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